

# State of the art and perspectives of gene therapy in heart failure. A scientific statement of the Heart Failure Association of the ESC, the ESC Council on Cardiovascular Genomics and the ESC Working Group on Myocardial & Pericardial Diseases

**Sophie Van Linthout<sup>1,2\*</sup>, Konstantinos Stellos<sup>3,4,5,6,7</sup>, Mauro Giacca<sup>8</sup>, Edoardo Bertero<sup>9</sup>, Antonio Cannata<sup>10</sup>, Lucie Carrier<sup>11,12</sup>, Pablo Garcia-Pavia<sup>13,14,15</sup>, Alessandra Ghigo<sup>16</sup>, Arantxa González<sup>17,18,19</sup>, Kristina H. Haugaa<sup>20,21</sup>, Massimo Imazio<sup>22</sup>, Luis R. Lopes<sup>23,24</sup>, Patrick Most<sup>25</sup>, Piero Pollesello<sup>26</sup>, Heribert Schunkert<sup>27,28</sup>, Katrin Streckfuss-Bömeke<sup>29,30,31,32</sup>, Thomas Thum<sup>33</sup>, Carlo Gabriele Tocchetti<sup>34</sup>, Carsten Tschöpe<sup>1,2,35</sup>, Peter van der Meer<sup>36</sup>, Eva van Rooij<sup>37,38</sup>, Marco Metra<sup>39</sup>, Giuseppe M.C. Rosano<sup>40,41,42</sup>, and Stephane Heymans<sup>43,44,45\*</sup>**

<sup>1</sup>Berlin Institute of Health (BIH) at Charité – Universitätsmedizin Berlin, BIH Center for Regenerative Therapies (BCRT), Berlin, Germany; <sup>2</sup>German Center for Cardiovascular Research (DZHK), partner site Berlin, Berlin, Germany; <sup>3</sup>Department of Cardiovascular Research, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany; <sup>4</sup>Department of Cardiology, Angiology, Haemostaseology and Medical Intensive Care, University Medical Centre Mannheim, Heidelberg University, Mannheim, Germany; <sup>5</sup>German Centre for Cardiovascular Research (DZHK), partner site Heidelberg/Mannheim, Mannheim, Germany; <sup>6</sup>Helmholtz Institute for Translational AngioCardioScience (HI-TAC), Mannheim, Germany; <sup>7</sup>Biosciences Institute, Vascular Biology and Medicine Theme, Faculty of Medical Sciences, Newcastle University, Newcastle, UK; <sup>8</sup>School of Cardiovascular and Metabolic Medicine & Sciences and British Heart Foundation Centre of Research Excellence, King's College London, London, UK; <sup>9</sup>Department of Medical Sciences, University of Trieste, Trieste, Italy; <sup>10</sup>Cardiovascular Unit, Department of Internal Medicine, University of Genova, Genova, Italy; <sup>11</sup>School of Cardiovascular and Metabolic Medicine & Sciences and British Heart Foundation Centre of Research Excellence, King's College London, London, UK; <sup>12</sup>German Centre for Cardiovascular Research (DZHK), partner site Hamburg/Kiel/Lübeck, Hamburg, Germany; <sup>13</sup>Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA, CIBERCV, Madrid, Spain; <sup>14</sup>Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain; <sup>15</sup>Universidad Francisco de Vitoria (UFV), Madrid, Spain; <sup>16</sup>Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center "Guido Tarone," University of Torino, Torino, Italy; <sup>17</sup>Program of Cardiovascular Diseases, CIMA and Department of Pathology, Anatomy and Physiology, Universidad de Navarra, Pamplona, Spain; <sup>18</sup>IdiSNA, Navarra Institute for Health Research, Pamplona, Spain; <sup>19</sup>CIBERCV (Network for Biomedical Research in Cardiovascular Disease), Instituto de Salud Carlos III, Madrid, Spain; <sup>20</sup>ProCardio Center for Innovation, Department of Cardiology, Oslo University Hospital, Rikshospitalet, Oslo, Norway; <sup>21</sup>Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway; <sup>22</sup>Department of Medicine (DMED), University of Udine, and Cardiothoracic Department ASUFC, University Hospital Santa Maria della Misericordia, Udine, Italy; <sup>23</sup>Institute of Cardiovascular Science, University College London, London, UK; <sup>24</sup>Barts Heart Centre, St Bartholomew's Hospital, London, UK; <sup>25</sup>Department of Cardiology, Angiology, Pulmonology, University Hospital Heidelberg, Heidelberg, Germany; <sup>26</sup>Content and Communication, Branded Products, Espoo, Finland; <sup>27</sup>Department of Cardiology, Deutsches Herzzentrum München, Technische Universität München, Munich, Germany; <sup>28</sup>German Center for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich, Germany; <sup>29</sup>Clinic for Cardiology and Pneumology, University Medical Center, Göttingen, Germany; <sup>30</sup>German Center for Cardiovascular Research (DZHK), Partner site Göttingen, Göttingen, Germany; <sup>31</sup>Institute of Pharmacology and Toxicology, University of Würzburg, Würzburg, Germany;

\*Corresponding author. Sophie Van Linthout, Translational Immunocardiology, Berlin Institute of Health at Charité – Universitätsmedizin Berlin, BIH Center for Regenerative Therapies (BCRT), Föhrer Strasse 15, 13353 Berlin, Germany. Tel: +49 30 450539486, Fax: +49 30 450539409, Email: sophie.van-linthout@bih-charite.de  
Stephane Heymans, Centre for Molecular and Vascular Biology, KU Leuven, Leuven, Belgium; Department of Cardiology, Maastricht University, CARIM School for Cardiovascular Diseases, Maastricht, The Netherlands. Tel: +31 43 3882950, Fax: +31 43 3882952, Email: s.heyman@maastrichtuniversity.nl

<sup>32</sup>Department of Translational Research, Comprehensive Heart Failure Center (CHFC), University Clinic Würzburg, Würzburg, Germany; <sup>33</sup>Institute of Molecular and Translational Therapeutic Strategies (IMTTS), Hannover Medical School, Hannover, Germany; <sup>34</sup>Department of Translational Medical Sciences; Center for Basic and Clinical Immunology Research (CISI); Interdepartmental Center for Clinical and Translational Research (CIRCET); Interdepartmental Hypertension Research Center (CIRIAPA), Federico II University, Naples, Italy; <sup>35</sup>Deutsches Herzzentrum der Charité (DHZC), Department of Cardiology, Angiology and Intensive Medicine, Campus Virchow Klinikum, Berlin, Germany; <sup>36</sup>Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands; <sup>37</sup>Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences (KNAW) and University Medical Center Utrecht, Utrecht, The Netherlands; <sup>38</sup>Department of Cardiology, University Medical Center Utrecht, Utrecht, The Netherlands; <sup>39</sup>Cardiology, ASST Spedali Civili di Brescia, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy; <sup>40</sup>Cardiovascular Clinical Academic Group, St. George's University Hospitals, NHS Trust, University of London, London, UK; <sup>41</sup>Cardiology, San Raffaele Cassino Hospital, Cassino, Italy; <sup>42</sup>Department of Human Sciences and Promotion of Quality of Life, San Raffaele University of Rome, Rome, Italy; <sup>43</sup>Centre for Molecular and Vascular Biology, KU Leuven, Leuven, Belgium; <sup>44</sup>Department of Cardiology, Maastricht University, CARIM School for Cardiovascular Diseases, Maastricht, The Netherlands; and <sup>45</sup>European Reference Network for Rare Low Prevalence and Complex Diseases of the Heart (ERN GUARD-Heart), Amsterdam, The Netherlands

Received 26 May 2024; revised 6 October 2024; accepted 23 October 2024; online publish-ahead-of-print 22 November 2024

Gene therapy has recently become a reality in the treatment of cardiovascular diseases. Strategies to modulate gene expression using antisense oligonucleotides or small interfering RNA are proving to be safe and effective in the clinic. Adeno-associated viral vector-based gene delivery and CRISPR-Cas9-based genome editing have emerged as efficient strategies for gene delivery and repair in humans. Overall, gene therapy holds the promise not only of expanding current treatment options, but also of intervening in previously untackled causal disease mechanisms with little side effects. This scientific statement provides a comprehensive overview of the various modalities of gene therapy used to treat heart failure and some of its risk factors, and their application in the clinical setting. It discusses specifically the possibilities of gene therapy for hereditary heart diseases and (non)-genetic heart failure. Furthermore, it addresses safety and clinical trial design issues and challenges for future regulatory strategies.

## Keywords

Adeno-associated viral vector • Gene editing • Gene replacement • Gene silencing • Gene therapy • Heart failure

## Introduction

The concept of gene therapy, a strategy to treat diseases using viral or non-viral vectors that introduce therapeutic exogenous genes into target cells and tissue to supplement or correct defective genes, was first formally proposed by Friedmann and Roblin in the 1970s.<sup>1</sup> Fifty years later, gene therapy has become a reality in treatment of cardiovascular diseases (CVD). In addition to adding genes using protein-coding cDNAs, strategies that enable precise gene editing using clustered regularly interspaced short palindromic repeat (CRISPR)-associated protein 9 (CRISPR-Cas9),<sup>2</sup> modulation of gene expression using RNA therapeutics (antisense oligonucleotides [ASOs], small interfering RNAs [siRNAs] and microRNAs [miRNAs])<sup>3–5</sup> and of protein expression using modified mRNA (modRNA) have entered the gene therapy field. Adeno-associated viral (AAV) vectors have become the gold standard for *in vivo* viral gene therapy,<sup>6</sup> while formulations based on polymers, lipids, peptides or other nano- or micro-sized particles have been developed as non-viral carriers (Figure 1).<sup>7</sup> Several gene therapies for cardiac diseases have been investigated in clinical trials, but success in clinical translation has been highly dependent on delivery technologies. Clinical success has been reached primarily with liver-directed therapies that target genes of risk factors underlying heart failure<sup>8–11</sup> or diseases in which proteins produced by the liver affect the heart and its vasculature.<sup>12</sup> However, gene therapies targeting the cardiac muscle have been less successful so far.<sup>13–15</sup> This scientific document provides an overview of existing gene therapy modalities and their clinical application, and discusses


the opportunities and challenges of gene therapy for non-genetic heart failure and inherited heart diseases.

## Updates on different modalities for gene therapy

### Antisense oligonucleotides and small non-coding RNAs (siRNAs and miRNAs)

Single-stranded ASOs and small non-coding RNAs (siRNAs and miRNAs) share a fundamental principle: an oligonucleotide binds a target RNA by Watson–Crick base pairing. An ASO must survive and function as a single strand. In contrast, an siRNA or miRNA, delivered as a small RNA duplex, is loaded within the RNA-induced silencing complex (RISC), whereupon one strand (the passenger strand) is discarded, and the remaining strand (the guide strand) cooperates with RISC to bind complementary RNA. This distinction between ASOs and siRNAs/miRNAs results in different strengths and weaknesses that affect drug development.<sup>16</sup> Unmodified single-stranded ASOs are too unstable to be used in cells. Their stability and pharmacological properties can be increased by incorporating chemical modifications.<sup>3,17,18</sup>

One category of ASOs targets endogenously expressed miRNAs, which have emerged as pivotal regulators in the pathogenesis of CVD, including atherosclerosis, arrhythmias, and heart failure. miRNAs modulate gene expression at the post-transcriptional level and play a critical role in regulating vascular function, cardiomyocyte hypertrophy, inflammation, and fibrosis, all of which



**Figure 1** Cardiac- and liver-directed gene therapy for heart failure and risk factors underlying heart failure. Main delivery methods, cargo, and targets currently used in gene therapy for heart failure and risk factors underlying heart failure distinguishing cardiac- and liver-directed gene therapy with the latter mainly focused on gene silencing/gene editing strategies (ASO, siRNA, CRISPR-Cas9) delivered via lipid nanoparticles. In contrast, cardiac gene therapy comprises adeno-associated viral- and lipid nanoparticle-mediated delivery strategies which may carry cDNA or modified mRNA, respectively, or modalities for gene silencing/editing/replacement (ASO, siRNA, miRNA, CRISPR-Cas9). Genes/mRNA for overexpression are outlined in black, silencing/editing/replacement targets are marked in red. ANGPTL3, angiotensin-like 3; ARVC, arrhythmogenic right ventricular cardiomyopathy; ASO, antisense oligonucleotide; ATTR, transthyretin amyloidosis; CM, cardiomyopathy; DCM, dilated cardiomyopathy; HCM, hypertrophic cardiomyopathy; LAMP2B, lysosome-associated membrane protein 2b; Lp(a), lipoprotein(a); MYBPC3, cardiac myosin-binding protein C; PCSK9, proprotein convertase subtilisin/kexin type 9; PKP2A, plakophilin 2a; PLN, phospholamban; RBM20, RNA binding motif protein 20; SERCA2a, sarcoplasmic/endoplasmic reticulum  $\text{Ca}^{2+}$  ATPase 2a; siRNA; small interfering RNA; TTR, transthyretin; VEGF-A, vascular endothelial growth factor-A. Created in BioRender. Van Linthout S. (2024) [BioRender.com/n39e845](https://www.biorender.com/n39e845)

are central to CVD development and progression.<sup>19</sup> Anti-miRNA ASOs have already progressed to clinical trials for heart failure and other CVD.<sup>20</sup>

While ASOs continue to be used for gene silencing, the robust nature of siRNAs and the relative ease of identifying active siRNAs through systematic screenings have made these molecules a preferred silencing tool.

One area where miRNA therapy appears particularly exciting is cardiac regeneration, as this process requires the reprogramming of cardiomyocytes to a proliferative state, which can be achieved by miRNAs due to their ability to simultaneously target multiple cellular mRNA targets.<sup>4</sup> In mice, single intramyocardial injection of the

pro-regenerative miR-199a-3p or miR-590-3p,<sup>21</sup> miR-19a/19b,<sup>22</sup> miR302b/c,<sup>23</sup> or miR-708<sup>24</sup> mimics, has been shown to promote cardiomyocyte proliferation, cardiomyocyte stress resistance and cardiac regeneration in response to myocardial ischaemia. Therapy with some of these miRNAs is now being investigated for efficacy and safety in large animal studies and will eventually be tested in clinical trials.

### Modified mRNAs

Modification of structural elements of mRNA – notably the 5' cap, 5'- and 3'-UTRs, the coding region, and the poly(A) tail – has

systematically improved its intracellular stability, reduced its immunogenicity (recognition via toll-like receptors) and increased its translational efficiency.<sup>25–28</sup> These improvements ultimately have led to the production of significant levels of the encoded protein over a longer timeframe. Consequently, the use of modRNAs has emerged as an appealing therapeutic tool for protein overexpression in heart disease.<sup>29–31</sup> The challenge still remains to improve modRNA delivery to achieve non-invasive, cell-specific delivery targeting the heart, the same challenge as with ASO, siRNA and miRNA. Moreover, protein expression is transient and repeated administration would be needed in chronic conditions.

Most research in this area has focused on ischaemic heart disease and myocardial infarction. A reduction in infarct size and improvement in cardiac function has been shown following application of modRNA for mutated human follistatin-like 1,<sup>32</sup> pyruvate kinase muscle isoform 2,<sup>33</sup> yes-associated protein,<sup>34</sup> acid ceramidase,<sup>35</sup> insulin growth like factor-1<sup>36</sup> and vascular endothelial growth factor-A<sup>37,38</sup> in mice or pigs. The success of this strategy has prompted its translation to human clinical trials (see below).

Interestingly, modRNAs have also been used to generate transient antifibrotic chimeric antigen receptor (CAR) T cells *in vivo* targeting activated fibroblasts.<sup>39</sup> Treatment with modRNA encoding a CAR against fibroblast activation protein encapsulated in CD5-targeted lipid nanoparticles reduced fibrosis and restored cardiac function in an experimental murine heart failure model, illustrating the potential of *in vivo* generation of CAR T cells as a therapeutic platform to treat various CVD.

## Non-viral carriers

Nucleic acids are hydrophilic, positively charged and susceptible to nuclease degradation, all of which are barriers to their delivery through cell membranes. Single-stranded ASOs are endocytosed and can pass freely through cellular membranes when administered as naked molecules.<sup>40</sup> Delivery of naked siRNA is more challenging since the RNA duplex is highly hydrophilic, making cellular permeability relatively modest. Targeting of both ASOs and siRNAs to hepatocytes is facilitated by their conjugation with N-acetylgalactosamine, which binds the asialoglycoprotein receptor, which is highly expressed on hepatocytes.<sup>41</sup> Conjugation with N-acetylgalactosamine is the most effective delivery method today, which allows specific delivery to the liver.<sup>41</sup> It is hoped that the discovery of new conjugations will allow more specific delivery to the heart and other organs or cells such as the kidney or inflammatory cells.

ModRNAs can be injected into the myocardium as naked molecules in sucrose citrate buffer,<sup>31,33</sup> but this requires relatively high doses. In most applications, RNA is therefore delivered using formulations based on polymers, lipids, peptides or other particles at the nano- or microscale.<sup>5</sup> Currently, the most successful formulations are lipid nanoparticles obtained by the stable nucleic acid lipid particle technology,<sup>7</sup> which were originally developed in the late 1990s, gradually improved<sup>42,43</sup> and popularized by the

mRNA-based COVID-19 vaccines. This technology is further instrumental for the development of *in vivo* CRISPR/Cas9 gene editing strategies directed to the liver.<sup>12</sup>

## Adeno-associated viral vectors

A family of vectors that is currently considered the gold standard for gene therapy and gene editing of the heart is based on cardiotropic serotypes of the small parvovirus AAV. AAV transduce postmitotic cells, especially cardiomyocytes, and can effectively, persistently and safely express foreign genes in host cells with low cytotoxicity and immunogenicity. Despite these unique characteristics, the ability to deliver the genetic payload (physical transduction) and achieve high transgene expression (functional transduction) remains the most important feature for the selection and improvement of AAV variants for clinical applications.<sup>6</sup>

As AAV capsid proteins play an essential role in delivery/tropism, AAV capsid variants have been generated for improved cardiac selectivity and liver de-targeting. Besides variants targeting cardiomyocytes,<sup>44</sup> variants based on AAV2<sup>45</sup> or AAV9<sup>46</sup> serotypes have also been generated to target endothelial cells. Moreover, AAV targeting cardiac fibroblasts<sup>47</sup> have recently been developed for therapies to counteract fibrosis and the fibro-inflammatory response therapeutically.<sup>48,49</sup> In addition to AAV-specific targeting of cardiac cells, selective promoters and enhancers for cardiac cell types (cardiomyocyte,<sup>50</sup> endothelial cell,<sup>51</sup> cardiac fibroblast) are used to avoid ectopic gene expression.

## Gene editing

CRISPR/Cas9 edits genes by precisely introducing double-stranded breaks into the DNA and then allowing natural DNA repair processes to take over. The system consists of two components: the Cas9 enzyme, which generates site-specific double-stranded breaks and a guide RNA, which directs the endonuclease to the site to be edited. Base editing allows the precise modification of a single base in the target site without causing double-stranded breaks,<sup>52</sup> with cytidine base editors (which convert a C-G base pair to T-A) and adenine base editors (which convert a A-T to G-C) being the two most commonly used editors so far.<sup>53</sup> Finally, prime editing enables precise correction of relatively long DNA segments, using a modified guide RNA carrying the desired sequence as a template.<sup>2</sup>

CRISPR-Cas9 gene editing technology is commonly used to correct specific genetic variants prior to disease onset,<sup>2</sup> as shown for the treatment of inherited cardiomyopathies in experimental models, as well as in hereditary transthyretin (TTR) amyloidosis (ATTR) (ATTRv) and familial hypercholesterolaemia. Recently, CRISPR-Cas9 adenine base editors have also been used in a murine ischaemia/reperfusion model to disrupt the pathological overactivation of calcium (Ca<sup>2+</sup>)/calmodulin-dependent protein kinase II $\delta$ , a primary driver of cardiac disease.<sup>54</sup> This cardioprotective strategy is potentially applicable to a broad range of patients with already-established heart disease. The concept of using

CRISPR-Cas9 to block the activation of harmful signalling pathways can also be translated to harmful signalling cascades in other human diseases.

## What has already reached the clinic?

Clinical trials evaluating gene therapy strategies for heart failure and risk factors underlying heart failure are outlined in Table 1, which gives an overview of their clinical endpoint, safety measures and clinical side effects.

### Small interfering RNA

#### Transthyretin amyloid cardiomyopathy

Patisiran is the first siRNA-based drug approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) in 2018 for the treatment of polyneuropathy of ATTRv.<sup>55</sup> ATTR cardiomyopathy is caused by the deposition of the misfolded TTR protein in the myocardium.<sup>56</sup> Since TTR is produced primarily by the liver, patisiran was encapsulated in lipid nanoparticles covered with apolipoprotein E, which mediated its internalization by hepatocytes via the low-density lipoprotein (LDL) receptor.<sup>57</sup> In the phase 3 APOLLO randomized controlled trial, patisiran improved neuropathy scores and gait speed in patients with ATTRv and polyneuropathy.<sup>55</sup> Non-invasive pressure–volume analysis of the APOLLO study demonstrated that patisiran may delay progression of left ventricular chamber dysfunction starting at 9 months of therapy.<sup>58</sup> In a predefined subpopulation of APOLLO, patisiran decreased mean left ventricular wall thickness, global longitudinal strain, N-terminal pro-hormone of brain natriuretic peptide (NT-proBNP), and adverse cardiac outcomes compared with placebo at month 18.<sup>59</sup> In the APOLLO-B trial, patisiran preserved functional capacity, as assessed by changes in 6-min walking test, and improved the quality of life after 1 year in patients with wild-type ATTR (ATTRwt) and ATTRv cardiomyopathy.<sup>60</sup> However, the FDA rejected the supplemental new drug application for patisiran to treat ATTRwt and ATTRv cardiomyopathy, citing insufficient evidence of clinical benefit.

Vutrisiran is another siRNA that prevents hepatic production of TTR. In contrast to patisiran, vutrisiran is directed to the liver by conjugation to N-acetylgalactosamine. Vutrisiran significantly improved multiple disease-relevant outcomes for ATTRv with polyneuropathy in the phase 3 HELIOS-A trial<sup>61</sup> and demonstrated evidence of potential benefit on exploratory cardiac parameters in HELIOS-A patients.<sup>62</sup> The HELIOS-B<sup>63</sup> trial showed that among patients with ATTR-cardiomyopathy, treatment with vutrisiran led to a lower risk of all-cause mortality and cardiovascular events than placebo and preserved functional capacity and quality of life.

Overall, siRNA-based agents targeting TTR production effectively halt neuropathy progression and maintain functional capacity in patients with ATTR-related neurological and cardiac involvement. Further investigations are warranted to

determine whether these agents can improve cardiovascular outcomes in ATTR cardiomyopathy patients and reverse the cardiac structural abnormalities associated with the disease.

#### Risk factors of cardiovascular disease and heart failure

Inclisiran is a siRNA that inhibits the translation of the proprotein convertase subtilisin/kexin type 9 (PCSK9), a serine protease that degrades the LDL receptor, which mediates LDL removal by the liver. Its efficacy in reducing LDL-cholesterol levels has been demonstrated in the phase 3 ORION-9 trial in patients with heterozygous familial hypercholesterolaemia<sup>8,9</sup> and in the subsequent ORION-10 and ORION-11 randomized controlled trials.<sup>64</sup> A patient-level analysis of the three ORION randomized controlled trials showed a lower incidence of major adverse cardiovascular events in patients treated with inclisiran compared to placebo.<sup>65</sup>

Furthermore, LDL-cholesterol levels could be reduced by blocking angiopoietin-like 3, a circulating inhibitor of lipoprotein lipase, the enzyme that clears triglyceride-rich lipoprotein from the circulation, and endothelial lipase.<sup>66</sup> Results from the phase 1 AROANG1001 study indicated that angiopoietin-like 3 silencing with the N-acetylgalactosamine-conjugated siRNA ARO-ANG3 was generally well tolerated and can effectively lower circulating concentrations of atherogenic lipoproteins.<sup>67</sup> Phase 2/3 trials are required to confirm the LDL reduction along cardiovascular outcome events.

Lipoprotein(a) is another lipoprotein whose levels strongly correlate with the risk of atherosclerotic CVD and cardiovascular events.<sup>68</sup> The phase 1 OCEAN-DOSE trial demonstrated that inhibition of hepatic lipoprotein(a) synthesis with the siRNA olpasiran abated lipoprotein(a) levels in patients with established atherosclerotic CVD.<sup>11</sup> Longer and larger trials are ongoing to determine the effect of olpasiran therapy on CVD outcomes [OCEAN(a)-Outcomes Trial, NCT05581303].

Finally, knockdown of hepatic angiotensinogen, the precursor of all angiotensins, via the siRNA zilebesiran markedly decreases serum angiotensinogen, the precursor of angiotensin II, and blood pressure for a duration of at least 24 weeks.<sup>10</sup> Zilebesiran is being further evaluated as a potential treatment for hypertension in two phase 2 studies: KARDIA-1 and KARDIA-2.<sup>69</sup>

### Antisense oligonucleotides

Inotersen is a 2'-O-methoxyethyl-modified ASO that targets the 3' untranslated region of human TTR mRNA, both wt and variant. In the NEURO-TTR phase 3 trial, inotersen improved the course of neurologic disease and quality of life of patients with ATTRv.<sup>70</sup> However, several adverse events occurred in the treatment group including injection site reactions, nausea, headache, glomerulonephritis and thrombocytopenia. For this reason, frequent monitoring of renal function and platelet count is advised during treatment.<sup>70</sup> A small single-centre, open-label study involving patients with ATTRwt- or ATTRv cardiomyopathy and New York Heart Association (NYHA) class I–III showed a reduction

**Table 1** Clinical trials evaluating gene therapy strategies for heart failure and for risk factors of heart failure.

| Modality/target organ |      | Drug/GTMP   |   | Carrier/ target |           | Cardiac disorder/ risk factor   |  | Admin. route   |   | Duration   |  | Clinical endpoint |  | Safety measures |  | Clinical side effect |  | Clinical trials |  |                |
|-----------------------|------|---|---|-----------------|-----------|---|--|--|---|--|--|-------------------|--|-----------------|--|----------------------|--|-----------------|--|----------------|
|                       |      |   |   |                 |           |   |  |  |   |  |  |                   |  |                 |  |                      |  |                 |  | Phase Name/NCT |
| siRNA/liver           | ATTR | ATTRv with polyneuropathy   | ATTRv with polyneuropathy   | s.c.            | 18 months | Improvement in neuropathy and polyneuropathy.   | Clinical laboratory tests, thyroid function, anti-drug antibodies, ECG, electroretinogram, vital signs. Premedications to reduce the likelihood of infusion-related reactions.                   | Mild or moderate infusion-related reactions. Overall incidence and types of SAE were similar in placebo and patisiran-treated group.   | 3 | APOLLO <sup>55</sup>                               |  |                   |  |                 |  |                      |  |                 |  |                |
|                       |      | ATTRv with polyneuropathy and evidence of cardiac amyloid involvement | ATTRv with polyneuropathy and evidence of cardiac amyloid involvement | s.c.            | 12 months | Reduction in LV wall thickness and NT-proBNP compared with both baseline and placebo. Preservation of functional capacity, health status and QOL. | Monitoring of cardiac AEs and cardiac arrhythmia AEs. Vitamin A supplementation  | Cardiac failure AEs were similar in the patisiran and placebo groups.  | 3 | Prespecified subpopulation of APOLLO <sup>59</sup> |  |                   |  |                 |  |                      |  |                 |  |                |
|                       |      | ATTR-CM   | ATTR-CM   | s.c.            | 18 months | Significant clinical benefits in multiple measures of QOL and physical function.  | AEs, clinical laboratory variables, vital signs  | Infusion-related reactions, arthralgia, and muscle spasms  | 3 | APOLLO-B, <sup>60</sup> NCT03997383                |  |                   |  |                 |  |                      |  |                 |  |                |
|                       |      | ATTR with polyneuropathy  | ATTR with polyneuropathy  | s.c.            | 36 months | Lower risk of death from any cause and CV events than placebo and preserved functional capacity and QOL.  | Treatment-emergent AEs, vitamin A supplementation  | Mild or moderate AEs, no drug-related discontinuations or deaths   | 3 | HELIOS-A <sup>61</sup>                             |  |                   |  |                 |  |                      |  |                 |  |                |
|                       |      | ATTR-CM   | ATTR-CM   | s.c.            | 540 days  | Reductions in LDL-cholesterol levels of approximately 50% were obtained.  | Patients randomized to patisiran received premedication to minimize risk of infusion-related reactions   | Incidence of AEs was similar in the two groups   | 3 | HELIOS-B, <sup>63</sup> NCT04153149                |  |                   |  |                 |  |                      |  |                 |  |                |
|                       |      | Familial hypercholesterolaemia  | Familial hypercholesterolaemia  | s.c.            | 16 weeks  | Reduction in triglyceride and non-HDL-cholesterol.  | AEs, laboratory values, vital signs, ECG, injection-site reactions, antidrug antibodies.   | AEs and SAEs were similar in the two groups.   | 3 | ORION-9 <sup>8</sup>                               |  |                   |  |                 |  |                      |  |                 |  |                |
|                       |      | Patients with elevated LDL-cholesterol                                | Patients with elevated LDL-cholesterol                                | s.c.            | 16 weeks  | Reduction in triglyceride and non-HDL-cholesterol.  | AEs, clinical laboratory values, antidrug antibodies.  | AEs were generally similar in the inclisiran and placebo groups in each trial, although injection-site AEs were more frequent with inclisiran than with placebo. Such reactions were generally mild, and none were severe or persistent.   | 1 | ORION-10 <sup>64</sup> ; ORION-11 <sup>64</sup>    |  |                   |  |                 |  |                      |  |                 |  |                |
|                       |      | Familial hypercholesterolaemia  | Familial hypercholesterolaemia  | s.c.            | 16 weeks  | Reduction in triglyceride and non-HDL-cholesterol.  | AEs or SAEs, physical examinations, ECG, injection site reactions, clinical laboratory tests levels, concomitant medications/therapy; and reasons for treatment discontinuation due to toxicity. | Well tolerated, no deaths, no life-threatening TEAEs or TAEs leading to drug discontinuation or premature withdrawal of any participant from the study. No treatment-related SAEs. No adverse changes in laboratory parameters. No clinically meaningful declines in platelet count. | 1 | AROANG1001 <sup>17c</sup>                          |  |                   |  |                 |  |                      |  |                 |  |                |

**Table 1 (Continued)**

| Modality/target organ            | Cardiac disorder/<br>risk factor   | Admin. route | Duration                                | Clinical endpoint   | Safety measures   | Clinical side effect  | Clinical trials                           |
|----------------------------------|--|--------------|---|---|---|---|---|
| Drug/GTMP                        | Carrier/<br>target   |              |   |   |   |   | Phase Name/NCT                            |
| Olpasiran                        | Increased Lp(a) in patients with established atherosclerotic cardiovascular disease. | s.c.         | 48 weeks                                | Significant reduction in Lp(a) concentrations.  | Monitoring of AEs and safety laboratory values.   | Overall incidence of AEs was similar across the trial groups. Injection-site reactions, primarily pain  | 1<br>OCEAN-DOSE <sup>11</sup>             |
| Zilebesiran                      | Hypertension   | s.c.         | 24 months                               | Dose-dependent decreases in serum angiotensinogen levels and 24-hour ambulatory blood pressure.   | Monitoring of AEs, laboratory assessments, and vital signs.   | Mild injection-site reactions   | 1<br>NCT03934307 <sup>10</sup>            |
| <b>ASO/liver</b><br>Inotersen    | ATTRv  | S.c.         | 15 months                               | Improvement in the course of neurologic disease and QOL.  | Collection of AEs, clinical laboratory tests, vital signs, ECG, and electroretinography examinations to detect early signs of vitamin A deficiency. Vitamin A supplementation.  | Injection site reactions, nausea, headache, glomerulonephritis and thrombocytopenia. Thrombocytopenia and glomerulonephritis were managed with enhanced monitoring. | 3<br>NEURO-TTR <sup>70</sup>              |
| Eplontersen                      | ATTR polyneuropathy and CM   | S.c.         | 65 weeks                                | Safe and effective in inhibiting progression and potentially reversing amyloid burden. Reduced TTR, lessened neuropathy and improved QOL. | Analysis of platelet count, monitoring of adverse renal effects. TEAEs, discontinuations due to TEAE, thrombocytopenia and glomerulonephritis, injection site reactions, flu-like symptoms, and TEAEs related to abnormal liver function were monitored. Vitamin A supplementation. | No signs of glomerulonephritis. Acceptable safety profile   | 3<br>NEURO-TTRransform <sup>72</sup>      |
| <b>Anti-miR/Heart</b><br>CDR132L | Stable chronic HF  | S.c.         | 6 months                                | Stable or improved measures of cardiac structure and function vs. historical placebo. Ongoing   |   |   | 3<br>NEURO-TTRransform <sup>73</sup>      |
|                                  | Acute myocardial infarction  | I.v.         | 6-month treatment + 6-month observation | CDR132L was safe and well tolerated and showed indications for cardiac functional improvements. Ongoing                                   | Platelet counts, laboratory assessments of liver and kidney function, hs-troponin T, ECG.   | Thrombocytopenia was not observed, no signs of hepatic or renal toxicity, no arrhythmia   | 1b<br>NCT04045405 <sup>79</sup>           |
|                                  |  |              |   |   | Clinical laboratory assessment, vital signs, physical examination, and ECGs.  | Ongoing   | 2<br>HF-REVERT, NCT05350969 <sup>80</sup> |

Table 1 (Continued)

| Modality/target organ | Carrier/target | Cardiac disorder/risk factor   | Admin. route | Duration   | Clinical endpoint  | Safety measures  | Clinical side effect   | Clinical trials | Phase Name/NCT                                  |
|-----------------------|----------------|--|--------------|--|--|--|--|-----------------|---|
| modRNA/heart          |                |  |              |  |  |  |  |                 |   |
| AZD8601               | VEGFA modRNA   | Patients with systolic dysfunction undergoing coronary artery bypass surgery | Epic.        | 6 months   | Safety and tolerability endpoints were met (primary endpoint).   | Echocardiography to assess haemopericardium and tamponade, AEs from surgery until end of follow-up and SAEs from informed consent until end of follow-up.                      | No deaths or treatment-related SAEs, no AEs of pyrexia or infection, immune reactions or arrhythmias, no negative impact on cardiac function | 2               | EPICURE <sup>83</sup><br>NCT03370887            |
| AAV/heart             |                |  |              |  |  |  |  |                 |   |
| AAV1/SERCA2a (AAV1)   | SERCA2a        | Advanced HF  | I.c.         | 12 months  | Evidence of biological activity in patients without preexisting anti-AAV1 antibodies. Reduction of clinical events and hospitalization times, reduction in NT-proBNP and improvement in cardiac structure. Neutral results | Antibodies to AAV1 capsid proteins, clinical laboratory values, vital signs, liver and kidney function. Antibodies to AAV1 capsid proteins (exclusion criteria), AEs and SAEs. | Acceptable safety profile  | 1/2             | CUPID <sup>13</sup>                             |
|                       |                |  |              | 12 months  |  |  | Well tolerated, with no untoward effects that can be attributed to AAV1/SERCA2a  | 2               | CUPID <sup>14</sup>                             |
|                       |                |  |              | at least 12 months                                 |  | AEs, AAV1 neutralizing antibody testing  | No safety concerns   | 2b              | CUPID2 <sup>85</sup>                            |
|                       |                |  |              | 12 months  | Trial was terminated prematurely.  | AEs, liver and renal markers, monitoring of implantable cardioverter-defibrillator.  | Well tolerated, with no untoward effects that can be attributed to AAV1/SERCA2a  | 2               | AGENT-HF <sup>15</sup>                          |
| BNP116 (AAV218)       | Inhibitor-1c   | Advanced HF  | I.c.         | 6 months   | Trial was terminated prematurely   | AEs, laboratory blood test, AAV1 neutralizing antibody testing. AEs, all-cause mortality, HF hospitalization.  | No safety concerns   | 2a              | SERCA-LVAD <sup>88</sup>                        |
| TN-201 (AAV9)         | MYBPC3         | HCM  | I.v.         | 12 months + 24 months via telephone questionnaires | Ongoing  |  | Ongoing  | 1               | NCT04179643                                     |
| RP-A601 (AAVrh.74)    | PKP2A          | ARVC   | I.v.         | 5 years  | Ongoing  | AEs and SAEs   | Ongoing  | 1               | MYPEAK-1,<br>NCT05836259                        |
| RP-A501 (AAV9)        | LAMP2B         | Danon Disease  | I.v.         | 12 months and 60 months                            | Ongoing  | TEAEs, SAEs and identification of dose limiting toxicities. AEs and SAEs   | Ongoing  | 1               | PKP2-ACM,<br>NCT05885412                        |
| CRISPR/Cas9/liver     |                |  |              |  |  |  |  |                 |   |
| NTLA-2001             | ATTR           | ATTRv with polyneuropathy  | I.v.         | 28 days  | Mild adverse events and decrease in serum TTR  | AEs and laboratory findings  | Mild AEs, no SAEs, coagulation and liver function measures remained within normal limits   | 1               | Interim results of<br>NCT04601051 <sup>12</sup> |
| VERVE-101             | PCSK9          | Familial hypercholesterolaemia   | I.v.         | 1 year   | Ongoing  | TEAEs, SAEs and AEs of special interest  | Ongoing  | 1b              | NCT05398029                                     |

AE, adverse event; ANGPTL3, angiotensin-like 3; ARVC, arrhythmogenic right ventricular cardiomyopathy; ASO, antisense oligonucleotide; ATTR, transthyretin amyloidosis; ATTRv, hereditary transthyretin amyloidosis; CM, cardiomyopathy; CV, cardiovascular; ECG, electrocardiogram; Epic., epicardial; GTPM, gene therapy medicinal product; HCM, hypertrophic cardiomyopathy; HDL, high-density lipoprotein; HF, heart failure; hs, high-sensitivity; i.c., intracoronary; i.v., intravenous; LAMP2B, lysosome-associated membrane protein 2b; LDL, low-density lipoprotein; LNP, lipid nanoparticle; Lp(a), lipoprotein(a); LV, left ventricular; modRNA, modified mRNA; MYBPC3, cardiac myosin-binding protein C; NT-proBNP, N-terminal pro-B-type natriuretic peptide; PCSK9, proprotein convertase subtilisin/kexin type 9; PKP2a, plakophilin 2a; QOL, quality of life; SAE, serious adverse event; SERCA2a, sarcoplasmic/endoplasmic reticulum Ca<sup>2+</sup> ATPase 2a; s.c., subcutaneous; siRNA, small interference RNA; TEAE, treatment-emergent adverse event; TTR, transthyretin; VEGFA, vascular endothelial growth factor-A.

in left ventricular mass and an improvement in exercise tolerance at a 2- and 3-year follow-up.<sup>71</sup> A further study is ongoing (NCT03702829).

Eplontersen is a novel ASO formulation that reduced serum TTR, lessened neuropathy impairment, and improved quality of life compared to a historical placebo in ATTRv polyneuropathy patients in the phase 3 NEURO-TTRtransform trial.<sup>72</sup> Eplontersen was associated with stable or improved measures of cardiac structure and function in patients with ATTRv polyneuropathy and cardiomyopathy compared to historical placebo.<sup>73</sup> The CARDIO-TTRtransform trial continues to investigate the effect of eplontersen on ATTR cardiomyopathy (NCT04136171). The primary endpoint is the change from baseline in the 6-min walk test distance at week 65, measuring physical function.

## Anti-miRNA

The therapeutic potential of targeting miRNAs in CVD is being extensively investigated in clinical trials. These trials aim to harness the potential of miRNAs as biomarkers for early diagnosis, prognosis, and as therapeutic targets. Various approaches are being explored,<sup>74,75</sup> including the use of miRNA mimics to restore miRNA levels, be it at lesser extent, and anti-miRNA oligonucleotides to inhibit the activity of disease-associated miRNAs. Furthermore, nanoparticle-mediated delivery systems are being developed to improve the targeted delivery of miRNA-based therapeutics. Based on *in vitro* and *in vivo* mode-of-action studies revealing reversal of cardiomyocyte hypertrophy, normalization of autophagy and Ca<sup>2+</sup> signalling, and reduction of cardiac fibrosis following treatment with the miR-132 inhibitor CDR132L,<sup>76–78</sup> CDR132L was tested in a first clinical study patients with stable chronic heart failure. In this study, CDR132L proved to be safe and well tolerated and already showed indications for therapeutic efficacy such as NT-proBNP reductions in addition to standard of care treatment.<sup>79</sup> A phase 2 study testing CDR132L in 280 patients with acute myocardial infarction and reduced ejection fraction (HF-REVERT) is ongoing (NCT05350969).<sup>80</sup> Primary outcome measure is the change in ejection fraction.

## Modified mRNAs


ModRNA for vascular endothelial growth factor-A has been tested for the treatment of heart failure.<sup>81</sup> A safety and tolerability randomized phase 1 clinical trial was performed in patients with type 2 diabetes mellitus and no other disease.<sup>82</sup> Intradermal injection of vascular endothelial growth factor-A modmRNA transiently increased the local expression of vascular endothelial growth factor-A protein and enhanced skin blood flow without relevant adverse side effects. A small, randomized, double-blind phase 2a study (EPICCURE) evaluating the safety and exploratory efficacy of a naked vascular endothelial growth factor-A modRNA (AZD8601; 3 mg/patient) in patients with systolic dysfunction undergoing coronary artery bypass surgery has been completed.<sup>83</sup> Seven patients received 30 epicardial injections of AZD8601 targeting ischaemic but viable myocardium identified by positron emission tomography, while four patients were injected with a placebo. The therapy

proved to be safe and showed preliminary subjective effects in patients, but the sponsor decided to discontinue its development in 2022.

## Adeno-associated viral vectors

The first phase 1/2 clinical trial in 2009 for the treatment of heart failure using AAV was based on an AAV1 vector that expressed the sarcoplasmic/endoplasmic reticulum Ca<sup>2+</sup> ATPase 2a (SERCA2a) cDNA, which was administered safely through intracoronary infusion.<sup>13</sup> The rationale for this trial was the observation that SERCA2a levels were lower in failing hearts and that overexpression of SERCA2a improved heart function in both small and large animals.<sup>84</sup> This first trial was followed in 2011 by a phase 2, double-blinded, randomized, placebo-controlled, multicentre study (the CUPID trial) with 39 patients with severe heart failure.<sup>14</sup> The results of this study demonstrated that the treatment was safe and led to significant improvement in cardiac function and a reduction in hospitalizations. Based on these findings, a larger, phase 2b, randomized, double-blind, multicentre trial, the CUPID2 study, was conducted in 250 patients with stable symptomatic heart failure of both ischaemic and non-ischaemic aetiology. Primary endpoint was the composite of recurrent heart failure-related events, and safety parameters included immune response monitoring (antibody, innate immunity and T-cell response to AAV1 vector) and viral shedding with detection of AAV1 vector DNA in bodily fluids. This trial, however, generated neutral results.<sup>85</sup> The possible reasons for the neutral results of CUPID2 have been extensively reviewed.<sup>15,86</sup> The most likely explanations are the low efficiency of myocardial transduction, possibly related to the relatively low dose of vector administered ( $1 \times 10^{13}$  AAV1.SERCA2a viral particles) and the suboptimal cardiomyocyte tropism of the AAV1 serotype, and the unaltered SERCA2a levels in human heart failure.<sup>87</sup> Two other related studies using the same vector – the AGENT-HF study, which evaluated efficacy in patients with left ventricular assist devices<sup>15</sup> and the SERCA-LVAD study,<sup>88</sup> which studied left ventricular remodelling – were prematurely terminated in 2016 as the sponsor suspended further enrolment following neutral results of the CUPID2 outcome trial.

A cardiotropic AAV variant (AAV2i8, also known as BNP116<sup>89</sup>) is currently being tested in a phase 1 clinical study in which a vector carrying the cDNA for a constitutively active form of inhibitor-1c is administered intracoronary (NCT04179643), and studied for its safety and tolerability in heart failure patients. Work in small and large animals has shown that inhibitor-1c inhibits the protein phosphatase-1, which dephosphorylates phospholamban (PLN) and thus blocks SERCA2a. Thus, the ultimate effect of this gene therapy approach is to increase SERCA2a levels and restore  $\beta$ -adrenergic stimulation.<sup>90</sup> In addition, clinical trials with AAV carrying cardiac myosin-binding protein C (MYBPC3) in hypertrophic cardiomyopathy (HCM), lysosome-associated membrane protein 2b (LAMP2b) in Danon disease and plakophilin 2a (PKP2A) in arrhythmogenic right ventricular cardiomyopathy (ARVC) patients are currently ongoing (see below, Table 1). These phase 1 trials using AAV vectors have safety and tolerability



as primary outcome, including immunogenicity and viral shedding as safety measures. In AAV gene therapy studies for liver diseases, hepatotoxicity is the most common adverse event,<sup>91</sup> and therefore, despite using AAV vectors with cardiac specific promoters, liver toxicity should and will be closely monitored.

## CRISPR-Cas9

The first CRISPR/Cas9-based treatment approved by regulatory authorities in late 2023 was a therapy for sickle cell disease and  $\beta$ -thalassemia to be administered *ex vivo* to hematopoietic stem cells before bone marrow transplantation.<sup>92</sup> Despite the enthusiasm in this field and the increasing number of CRISPR-based treatments in clinical trials each year, adapting CRISPR/Cas9 technologies to *in vivo* applications for organs other than the liver remains a challenge. One of the best known examples of successful CRISPR/Cas9-based *in vivo* gene editing in humans is the treatment of ATTR.<sup>12,93</sup> A liver-targeted lipid nanoparticle delivery system called NTLA-2001, administered by intravenous infusion, decreased serum TTR protein levels up to 87% in six patients with ATTRv.<sup>12</sup> In the follow-up of this trial (NCT04601051), a single intravenous infusion of NTLA-2001 significantly reduced abnormal TTR levels in ATTR cardiomyopathy patients.<sup>94</sup> Still, the primary outcome of these phase 1 trial include safety and tolerability, and further studies are needed for proving their efficacy.

Another example of liver-directed CRISPR-editing using lipid nanoparticles is the base-editing of PCSK9. Supported by pre-clinical evidence in mice and macaques<sup>95,96</sup> showing stable reduction of plasma PCSK9 and LDL-cholesterol levels without adverse side effects, this base-editing technology is currently being evaluated in a phase 1b trial in patients with established atherosclerotic CVD due to heterozygous familial hypercholesterolemia (NCT05398029), with safety and tolerability as primary outcomes, with therapeutic efficacy as secondary endpoint. Distinct safety measures for CRISPR-editing includes (i) detailed assessment of potential off-target editing to ensure that base editing is confined to the targeted gene without unintended modifications elsewhere in the genome; (ii)

evaluation of immune responses against the components of the gene-editing system, including any potential immune reaction to the delivery vector.

## What are the future perspectives for the treatment of genetic cardiomyopathies?

Cardiomyopathies are either inherited (genetic/familial) and/or acquired. They can also be accelerated by disease modifiers. They are a heterogeneous group of diseases and major causes of heart failure. Dilated cardiomyopathy has an estimated prevalence of 1 in 250 to 1 in 2500 of the general population, HCM ranges between 1 in 250 to 1 in 500, and ARVC is estimated to be present in around 1 in 1000 to 1 in 5000 people.<sup>97–99</sup> The current pharmacological treatment of heart failure in cardiomyopathy patients does not significantly differ from general heart failure management.<sup>100</sup> Phenotype- or genotype-specific drugs are under investigation, with mavacamten being the first disease-specific drug for inherited HCM, with the exception of ATTRv. In a phase 3, randomized, double-blind, placebo-controlled trial (EXPLORER-HCM), treatment with mavacamten improved exercise capacity, left ventricular outflow tract obstruction, NYHA functional class, and health status in patients with obstructive HCM.<sup>101</sup> Mavacamten selectively binds to the myosin motor domain, reducing the ATPase activity of myosin. This inhibition decreases the interaction between myosin heads and actin filaments, leading to a reduction in the force of cardiac muscle contraction. As such, mavacamten stabilizes myosin heads in a 'super-relaxed' state, a low-energy conformation. Gene-specific treatments, based upon molecular profile or specific cellular, metabolic, contractile, immune or pro-fibrotic pathways hold therefore great promise, but require further molecular studies to understand the complex mechanisms leading from genetic variants to disease manifestation. Nevertheless, the most logical way to cure an inherited cardiomyopathy would certainly be by gene silencing, replacement or correction (Figure 2), depending on the type of disease-causing genetic variant (poison peptide or loss-of-function). Still, these approaches – in particular AAV and CRISPR – as described in this review still have major challenges

in safety, immunogenicity, aspecific gene editing, and long-term efficacy.

## Silencing gene therapy

Allele-specific silencing with siRNA or ASO can be used to silence a poison gene product from a mutated allele. In a homozygous *PLN R14del*-associated cardiomyopathy mouse model, administration of PLN-ASO led to a dose-dependent reduction in PLN. Furthermore, this PLN-ASO prevented PLN protein aggregation, reduced cardiac dysfunction, and increased survival rate in mice.<sup>102,103</sup> In a *Mybpc3*-targeted knock-in mouse model of HCM, skipping of a mutated exon 6 in the *Mybpc3* gene utilizing AAV-mediated ASO transfer resulted in decreased levels of incorrectly spliced mRNA, restored cardiac function, and halted the development of left ventricular hypertrophy.<sup>104</sup> Similarly, allele-specific silencing of mutant *Myh6* transcripts via AAV-mediated siRNA suppressed HCM in R403Q heterozygous mice.<sup>105</sup>

## Gene replacement therapy

Gene replacement therapy consists of the introduction of a fully functioning gene to replace a loss-of-function genetic variant in target cells. Loss-of-function variants are non-sense, splice, or insertion-deletions causing a frameshift and a premature termination codon (commonly referred to as 'truncating' variants, even though the truncated protein is rarely present, due to active degradation of the mutant transcript by the nonsense-mediated RNA decay).<sup>106,107</sup> Loss-of-function variants are common causes of cardiomyopathy in several genes involved in all cardiomyopathies, HCM (*MYBPC3*)<sup>108</sup>, dilated cardiomyopathy (*titin* [*TTN*]),<sup>109</sup> Bcl-2-associated athanogene 3 (*BAG3*),<sup>110</sup> filamin C (*FLNC*),<sup>111</sup> desmoplakin (*DSP*)<sup>112</sup> and ARVC (*PKP2*).<sup>113</sup>

Gene replacement therapy has been tested in mouse or human cellular models of HCM (*MYBPC3*) and ARVC (*PKP2*). It is worth noting that gene replacement therapy may also be effective for missense variants in sarcomeric proteins, because of stoichiometric replacement of endogenous protein. For *MYBPC3*, it has been shown that AAV9-*Mybpc3* prevented the development of the cardiomyopathic phenotype in *Mybpc3*-deficient mice<sup>114</sup> and rescued cell hypertrophy in patient-derived induced pluripotent stem cell (iPSC)-derived cardiomyocytes.<sup>115</sup> These proof-of-concept studies motivated the development of a *Mybpc3* gene therapy medicinal product, TN-201, which is now tested in a phase 1 clinical study (NCT05836259) (Table 1). Similarly, *Pkp2* gene therapy has been shown to reduce ventricular arrhythmias, reverse right ventricular remodelling, improve cardiac function and prolong survival in a *Pkp2*-deficient mouse model of ARVC.<sup>116</sup> A gene therapy medicinal product, RP-A601 (AAVrh.14-PKP2a), is now evaluated in a phase 1 trial (NCT05885412) (Table 1).

An additional gene replacement therapy relevant to cardiomyopathy is RP-A501. It is designed to address Danon disease, a rare X-linked monogenic condition, caused by mutations in the *LAMP2B* gene that often leads to heart failure due to massive left ventricular hypertrophy, and in male patients to frequent death in adolescence or earlier.<sup>117</sup> Evaluation of RP-A501, an AAV with a normal copy

of the human *LAMP2B* gene (AAV9:LAMP2B), is currently ongoing in a phase 2 trial (NCT06092034) (Table 1).

## Gene editing therapies

In the context of heart failure, studies have now shown *in vitro* (hiPSC-derived cardiomyocytes) and *in vivo* efficacy of base editing by correcting specific pathogenic variants for lamin A/C (*LMNA*), RNA binding motif protein 20 (*RBM20*), myosin heavy chain 6 (*MYH6*) and myosin heavy chain 7 (*MYH7*) in relevant disease models.<sup>118–122</sup> Beyond correcting disease-causing variants, base editing can also be used for exon skipping, which has shown therapeutic relevance particularly in the context of Duchenne muscular dystrophy.<sup>123,124</sup>

Prime editing is of particular interest for modelling and correcting variants associated with cardiac disease because it can target a wide range of single nucleotide variants and more complicated types of genetic alterations (such as short deletions or insertions).<sup>125</sup> While multiple studies have successfully used prime editing in hiPSC-derived cardiomyocyte cultures<sup>123,126,127</sup> and *in vivo*,<sup>119</sup> this technology so far remains less developed due to lower efficiency rates.

## Safety

Many advances have been made in the management of acute effects related to gene therapies. However, the potential for delayed effects remains a concern, particularly since most gene therapies are designed to achieve permanent or long-lasting effects in the human body, and this inherently increases the risk of delayed adverse events.<sup>128</sup> Published evidence of long-term safety (>1 year) in pre-clinical setting is rare and has been shown for AAV-mediated gene therapy outside the cardiovascular field, in the canine model of haemophilia A after a median follow-up of 10.8 years.<sup>129</sup> In the cardiovascular field, follow-up of gene therapy for 6 months or 1 year in large animal models including pigs and non-human primates have been reported.<sup>12,78</sup> As far as the safety profile of cardiovascular gene therapy in patients is concerned, trials have shown a very good safety profile even after 10-year follow-up for AAV gene transfer overexpressing a gene of interest.<sup>130–132</sup> In general, safety concerns of gene therapy should be differentiated depending on the gene therapy modality used. In 2020 the FDA updated guidelines on the design of long-term follow-up studies for the collection of data on delayed adverse events following the administration of a gene therapy product. For studies using integrating vectors and genome-editing products, patients should be followed up for at least 15 years, while for AAV, a minimum 5-year follow-up period is recommended. These recommendations are aligned with those suggested by European Union regulators.<sup>128</sup>

An overview of adverse side effects of gene therapy modalities and mitigation strategies is listed below and in Table 2.

## Adverse side effects of oligonucleotides

While oligonucleotide therapies offer exciting possibilities for novel therapeutic approaches, they are not free of potential adverse

**Table 2** Adverse effects of gene therapy modalities

| Gene therapy modality                                      | Adverse effects  | Mitigation strategies  |
|--|--|--|
| <b>Targeted gene silencing and regulation therapy</b>      |  |  |
| Oligonucleotides <sup>133,134</sup><br>(ASO, siRNA, miRNA) | Off-target effects                                       | <ul style="list-style-type: none"> <li>• Selection of sequences with high target specificity and minimal off-target potential via bio-informatics.</li> <li>• Study of endogenous RNA modifications, RNA structure and RNA-binding protein binding sites at or near the target sequence to increase the understanding of RNA biology at the target site of interest.</li> <li>• Use of chemically modified nucleotides to increase specificity.</li> <li>• Pre-clinical testing.</li> </ul>  |
|  | Immunogenicity   | <ul style="list-style-type: none"> <li>• Use of biocompatible and biodegradable materials for RNA delivery minimizing long-term effects.</li> <li>• Targeted delivery: development of targeting ligands on delivery systems to ensure specific delivery to the affected tissues, reducing systemic exposure.</li> <li>• Chemical modifications to the oligonucleotide to reduce immunogenicity.</li> <li>• RNA molecule encapsulation in lipid nanoparticles to shield them from immune surveillance.</li> <li>• Dose adjustment to minimize immune activation while maintaining therapeutic efficacy.</li> <li>• Anti-inflammatory drug administration before or after the treatment.</li> <li>• Pre-clinical testing.</li> </ul>   |
|  | Liver toxicity   | <ul style="list-style-type: none"> <li>• Monitoring of liver toxicity.</li> <li>• Delivery optimization.</li> <li>• Pre-clinical testing.</li> </ul>   |
|  | Renal toxicity   | <ul style="list-style-type: none"> <li>• Monitoring of renal toxicity.</li> <li>• Delivery optimization.</li> <li>• Proper hydration before and during treatment to reduce renal accumulation.</li> <li>• Pre-clinical testing.</li> </ul>   |
|  | Injection site reactions<br>(pain, swelling, or redness) | <ul style="list-style-type: none"> <li>• Documentation of local site reactions.</li> <li>• Delivery optimization.</li> <li>• Pre-clinical testing.</li> </ul>  |
|  | Thrombocytopenia and coagulation disorders               | <ul style="list-style-type: none"> <li>• Documentation of systemic immune responses and monitoring of leucocyte and platelet counts, coagulation, temperature and flu-like symptoms. In case of thrombosis, search for secondary causes.</li> <li>• Monitoring of bleeding history, coagulation molecules, haemoglobin and platelet count before therapy application.</li> <li>• Delivery optimization.</li> <li>• Dose schedule optimization by increasing the time intervals between drug administration regimes to enable the platelet count and the coagulation system to recover before the next treatment.</li> <li>• Therapy discontinuation if therapy interferes with blood cell production.</li> <li>• Pre-clinical testing.</li> </ul>  |
|  | Hypersensitivity and allergic reactions                  | <ul style="list-style-type: none"> <li>• Pre-treatment screening for allergies or hypersensitivity to any components of the RNA therapeutic or its delivery system.</li> <li>• Documentation of systemic immune responses and monitoring of leucocyte counts, temperature and flu-like symptoms.</li> <li>• For patients with mild allergies, gradual dose escalation or pre-treatment with antihistamines or corticosteroids to mitigate hypersensitivity reactions.</li> <li>• Regularly monitoring for signs of autoimmunity during and after treatment to intervene early if symptoms arise.</li> <li>• Therapy discontinuation in case of involvement of a systemic adaptive immune response and consideration for alternative delivery systems if hypersensitivity to a specific delivery vehicle is confirmed.</li> </ul> |

**Table 2 (Continued)**

| Gene therapy modality                 | Adverse effects   | Mitigation strategies   |
|---------------------------------------|---|---|
|                                       | CNS effects (headaches, mood alterations, or dizziness) | <ul style="list-style-type: none"> <li>• Documentation of CNS effects.</li> <li>• Presentation to a neurology specialist in case of symptom persistence.</li> <li>• Design RNA therapeutics with restricted ability to cross the blood–brain barrier unless CNS targeting is intended.</li> <li>• Discontinuation in case of drug penetrations across the blood–brain barrier.</li> <li>• Pre-clinical testing.</li> </ul>  |
| <b>Targeted gene repair therapy</b>   |   |   |
| AAV <sup>135–138</sup>                | Immunogenicity  | <ul style="list-style-type: none"> <li>• Screening of pre-existing neutralizing antibodies against AAV.</li> <li>• Immunosuppressive (pre-) treatment.</li> <li>• Vector design optimization and shielding to escape the immune system surveillance.</li> <li>• Preclinical testing.</li> <li>• Regularly monitoring for signs of autoimmunity during and after treatment to intervene early if symptoms arise.</li> </ul>  |
|                                       | Liver toxicity  | <ul style="list-style-type: none"> <li>• Monitoring of liver function</li> <li>• Development of AAV variants for liver de-targeting and improved cardiac targeting.</li> <li>• Use of engineered nanoparticles to promote cardiac tropism.</li> <li>• Preclinical testing.</li> </ul>   |
|                                       | Insertional mutagenesis                                 | <ul style="list-style-type: none"> <li>• Long-term follow-up studies, including genetic monitoring of vector-treated tissues.</li> </ul>  |
| <b>Precision gene editing therapy</b> |   |   |
| CRISPR-Cas9 <sup>139–146,154</sup>    | Off-target effects leading to mutations and DNA damage  | <ul style="list-style-type: none"> <li>• Improved Guide RNA Design: design of highly specific guide RNAs with optimized algorithms to reduce off-target effects.</li> <li>• High-fidelity Cas9 variants: use of engineered Cas9 variants with reduced off-target activity to minimize off-target cuts.</li> <li>• Chemical modifications of CRISPR/Cas9</li> <li>• <i>In silico</i> prediction tools to predict on-target efficiency and on- and off-target activity</li> <li>• Whole exome sequencing as a diagnostic tool to detect off-target effects, at least in preclinical setting.</li> <li>• Use of transient expression of Cas9 delivery systems.</li> <li>• Use of self-limiting vectors that are biodegraded after gene delivery.</li> <li>• Pre-treatment with immunosuppressive drugs to reduce immune reactions against Cas9, which is a bacterial protein and may trigger an immune response.</li> <li>• Chemical modifications to the guide RNA oligonucleotide to reduce immunogenicity.</li> <li>• Monitoring of systemic immune responses.</li> <li>• Anti-inflammatory treatment.</li> </ul> |
|                                       | Immunogenicity  | <ul style="list-style-type: none"> <li>• Comprehensive genomic screening including whole-genome sequencing.</li> <li>• Use of base-editing or prime-editing strategies that are less likely to cause large genomic alterations.</li> <li>• Use of tissue-specific promoters to avoid systemic effects.</li> <li>• Use of targeted delivery systems.</li> </ul>  |
|                                       | Genomic instability                                     | <ul style="list-style-type: none"> <li>• Strict regulation and therapy administration monitoring</li> <li>• Public engagement and transparency.</li> </ul>  |
|                                       | Ethical concerns in case of germline editing            |   |

AAV, adeno-associated virus; ASO, antisense oligonucleotide; CNS, central nervous system; miRNA, microRNA; siRNA, small interfering RNA.

side effects,<sup>133,134</sup> including those listed in Table 2. In general, the occurrence and severity of these side effects can vary depending on the specific oligonucleotide, its mode of delivery, and individual patient factors. It is important that potential adverse effects are intensively investigated during the safety and toxicological evaluation in the pre-clinical phase. Clinical trials are crucial to thoroughly assess and manage the safety profile of oligonucleotide therapies and ensure their optimal and responsible use in the medical field.

## Adverse side effects of adeno-associated viral vectors

Immunogenicity is a significant concern with AAV-based gene therapies due to the body's immune response to the viral vector (reviewed in references<sup>135,136</sup>). Many individuals have been exposed to wild-type AAVs, leading to pre-existing antibodies that can neutralize the vector, reducing its effectiveness. AAV vectors can trigger innate immune responses shortly after administration, including the activation of complement pathways and the inflammasome.<sup>137</sup> The capsid proteins of AAV can be recognized by the adaptive immune system, leading to the activation of T cells that may attack transduced cells, reducing gene expression and potentially causing tissue (liver/cardiac) damage. Therefore, patients will get immunosuppressive treatment during 2–3 months, favouring fluid retention, which may be challenging in heart failure patients.

Another important concern is the liver toxicity as AAV vectors accumulate in the liver.<sup>135</sup> Higher doses of AAV vectors increase the likelihood of hepatotoxicity, which can manifest as elevated liver enzymes, inflammation, and, in severe cases, acute liver failure, resulting in death. The immune responses against the AAV capsid or transgene can lead to cytotoxicity in liver cells, causing inflammation and tissue injury. Mitigation strategies include careful dose selection to balance therapeutic benefits and minimize liver toxicity, provide immunosuppression to minimize the immune response in the liver. Regular monitoring of liver function tests to detect early signs of hepatotoxicity is therefore required. Specific AAV capsid variants have been generated to improve liver de-targeting and cardiac targeting as well as engineered nanoparticles to promote cardiac tropism of AAV vectors (see up and below).<sup>138</sup>

## Adverse side effects of CRISPR-Cas9

A major concern with CRISPR-Cas9 gene editing is the off-target effects of this gene-editing tool, where unintended editing events of unrelated genes can lead to mutations and DNA damage.<sup>139</sup> Off-target mutations occur more frequently than expected mutations when CRISPR/Cas9 is used.<sup>140</sup> These off-target mutations not only disrupt the functionality of unrelated genes, but can also induce genomic instability.<sup>140</sup> Recent findings reveal that the expression of Cas9 protein in pigs significantly increases genomic damages, induces transcriptome changes, and enriched genomic mutations with prolonged expression of Cas9 resulting in growth retardation and alterations of key tumor-driving genes in the

absence of direct tumour development.<sup>141</sup> Various modifications of the CRISPR/Cas9 system have been proposed to address this issue. *In silico* prediction tools are used to predict the on-target efficiency and enable the development of improved algorithms to predict on- and off-target activity.<sup>142</sup> Additionally, chemical modifications to guide RNA have been proposed to minimize the probability of off-target DNA cuts.<sup>143</sup> Regulating the activity of Cas9 is also crucial for safe and efficient editing. Optimizing Cas9 by engineering high-fidelity variants, adding cytosine extensions to single-guide RNAs, or using Cas9-targeting guide RNA to restrict CRISPR expression have been shown to reduce off-target effects.<sup>144–146</sup> The immunogenicity of the CRISPR-Cas9 system has also been reported as a detrimental feature. It may lead to frequent activation of p53, DNA damage, large-scale on-target genomic deletion and chromosomal rearrangement.<sup>147–150</sup>

The half-life of the editors in the cells has a major influence on the activity and reliability of gene editing. The methods by which Cas9/single guide RNA is introduced into target cells, such as plasmid transfection, ribonucleoprotein, electroporation, or viral transduction, may affect its off-target effects.<sup>151</sup> AAV and lipid nanoparticles are commonly used vectors for *in vivo* gene therapy. AAV9 is effective in infecting the hearts of mice and large mammals,<sup>54</sup> but it may accumulate off-target mutations over time due to its long-lasting expression.<sup>152,153</sup> On the other hand, lipid nanoparticles can be rapidly degraded *in vivo*, making them popular for gene editing.<sup>154</sup> In this regard, lipid nanoparticle-encapsulating Cas9/single guide RNA targeting TTR has been shown to be a safe and efficient form of delivering gene editing tools in patients.<sup>12</sup> However, it is important to point out that these reflect interim results until day 28 post application, whereas patients will be long-term followed up.

## Design of clinical studies and regulatory strategies

Gene therapies are still in their infancy. To date 26 gene therapy products have been approved worldwide.<sup>155</sup> Guidelines by the regulatory agencies FDA<sup>156</sup> and EMA are expected to further accelerate clinical application in this area and provide greater clarity for manufacturers and healthcare professionals.<sup>157</sup> The role of the pharmaceutical industry in securing the investments needed for the expensive regulatory trials allowing full clinical development (from phase 1 to 4) cannot be ignored in this process.<sup>158</sup> Therefore, it is advised to be aware – even in the early stages of research – not only of the therapeutic potential of a novel therapy, but also of its potential to become both realistic and attractive to the pharmaceutical industry.<sup>159</sup> The requirements for such trials – and the timeframe for the development phase – can be considerably reduced for rare diseases and orphan drugs, or if the clinical phase can be optimized through innovative features such as adaptive designs, umbrella or basket designs, or n-of-1 trials.<sup>158</sup> In the cardiology field, however, the traditional phase 1, 2, 3 design is still followed in most cases. However, it is acceptable to conduct phase 1 trials directly in patients with heart failure or the specific disease phenotype of interest without a preliminary phase in healthy

volunteers, as was done in a recent antisense RNA trial in heart failure patients.<sup>79</sup> This is one way of making drug development faster and more efficient without compromising on safety. The safety and efficacy requirements defined by the regulatory authorities and guideline committees for the approval and indications of drugs must of course also apply for novel gene therapies.

## Future new modalities for viral and non-viral therapy

### Cardiac targeting

In contrast to the success in the development of AAV variants with improved cardiac targeting and liver de-targeting (see before),<sup>86,160,161</sup> specific targeting of cardiomyocytes and liver detargeting has been more problematic so far for non-viral RNA delivery. This is due to the fact that there is no molecule like N-acetylgalactosamine in the liver for any cardiac cell type. Most of the systemically administered nucleic acid-containing nanoparticles are phagocytosed by mononuclear cells in the spleen, lymph nodes and bone marrow or end up in the liver, and only a small proportion is retained in the heart. Cardiac retention, however, is increased after acute damage and inflammation, such as myocardial infarction. This is thanks to the transient vascular permeability and retention effect, by which relatively large fenestrations form between endothelial cells, permitting nanosized particles to extravasate from the circulation into the inflamed tissue.<sup>162</sup>

A number of cardiac-specific peptides have been identified that can be conjugated by nanoparticles to enhance cardiac targeting. These have been identified by screening phage display libraries or are ligands for or antibodies against endogenous cardiomyocyte or endothelial receptors.<sup>5</sup> Recent evidence demonstrates that cargo-less, safe poly (lactic-co-glycolic acid) particles can drastically improve heart delivery of AAVs and nanoparticles based on the interaction of the glucose–GLUT axis, circumventing active targeting (e.g. via epitope recognition) or serotype engineering for AAV.<sup>138</sup>

While these targeting technologies are promising but do not yet appear to be mature for clinical application, with liver detargeting remaining a major unsolved issue, the heart can however be reached through direct intravascular catheterization for local vector or RNA administration. In the case of vascular infusion, this can be done anterograde through the coronary arteries or retrograde from the coronary sinus, or, in the case of intramyocardial injection, trans-endocardial from the left ventricle.<sup>86</sup>

### Delivery route

Choosing the best approach for cardiac gene therapy delivery – whether intracoronary, intravenous, intramyocardial or epicardial – depends on factors like the target cardiac disease, desired gene expression level, and invasiveness. Intracoronary delivery is often favoured for its ability to target the heart with less invasiveness compared to direct intramyocardial

injections, and higher transduction efficacy in the target area and a reduced off-target contamination compared to systemic intravenous application. Antegrade delivery however, may be impaired by coronary heart disease, such as stenosis or occlusion of a coronary artery. Coronary veins appear not to be affected and might therefore be the preferable application route for gene therapy.<sup>163</sup> For an effective and safe retrograde application, selective catheterization of the coronary vein draining the target area is necessary. A selective pressure regulation of retrofusion enhances safety and seems to be a favourable approach for gene therapy transduction in combination with reduced systemic contamination.<sup>163</sup> Intracoronary application paired with proximal balloon occlusion to limit competitive flow, results in efficient uptake of both AAV and similarly sized nanoparticles and allows for delivery to the entire vascular bed of interest and regions of the heart not easily reached via epicardial injection.<sup>164</sup> Epicardial approaches offer more precise delivery but are also more invasive. Non-invasive, intratracheal administration is used for gene therapy directed to treat pulmonary hypertension.<sup>165</sup> For AAV gene therapy, mostly the intravenous route is now being tested in view of the cardiac promoters that allow high cardiac specificity of gene overexpression.<sup>166</sup>

Ultrasound-assisted gene delivery to the heart is an exciting and emerging methodology showing tremendous advancements in pre-clinical models to date, reinforcing the idea that translation of contrast echocardiography-mediated localized cardiac gene delivery is a feasible near-term objective.<sup>167</sup> Further investigations in large animal models are warranted to understand the implications of each technique for AAV- and nanoparticle-based therapeutic outcomes.

### RNA editing with CRISPR/Cas9

In addition to targeted DNA mutagenesis, the CRISPR/Cas system can edit various types of RNA, such as miRNA, long-noncoding RNA, and mRNA.<sup>168</sup> Aberrant m6A RNA methylation and dysregulated adenosine-to-inosine editing, mediated by the enzymes adenosine deaminases acting on RNA (ADARs)<sup>169,170</sup> contribute to the development of heart failure.<sup>171,172</sup> The combination of CRISPR/Cas technology with single-chain m6A methyltransferase or demethyltransferase enables site-specific insertion or deletion of m6A modifications.<sup>173</sup> In addition, several innovative RNA editing platforms have been developed to perform targeted RNA base conversions mediated by ADARs.<sup>168,174–176</sup> These RNA editing systems exhibit versatility, high specificity, and efficiency and facilitate the editing of full-length mRNA transcripts containing disease-associated point mutations.<sup>177</sup>

RNA editing is considered less risky than DNA editing because it is only transient and may not cause off-target mutations.<sup>169</sup> RNA editing/modifying platforms are therefore promising additions to existing CRISPR/Cas systems.

## Conclusion

Advances in gene therapy including the advent of CRISPR genome editing and improved targeting and silencing strategies, have

launched a new era of cardiovascular research, enabling targeted therapeutics and improved implementation of precision and personalized medicine. To date, clinical success has been achieved primarily with gene therapies targeting the liver, but there have also been initial breakthroughs in the development of cardiac-directed therapies for inherited cardiomyopathies in pre-clinical models. In addition, pivotal clinical trials are currently underway to test cardiac gene therapy for cardiomyopathies. Despite the many advances in the field of gene therapy, there is still much to learn. A better understanding of the consequences of introducing lifelong genetic modifications and the safety profile of these editing techniques will be crucial for the development of gene editing-based therapies for cardiac conditions. Further improvements in tissue-specific delivery through chemical modifications, bioconjugation and the use of nanocarriers may ultimately lead to reduced toxicity, lower immunogenicity and better efficacy. With regard to anti-miRNAs in CVD, further research is needed to uncover the complex regulatory networks involved to ensure the safety and efficacy of miRNA-based therapies. Overall, gene therapy has the potential to transform treatment strategies aimed at alleviating symptoms and complications into strategies that address the underlying causes of diseases. Further success of this promising but delicate field of future medical treatment will depend on close cooperation between regulatory authorities, the pharmaceutical industry, patients and research institutions.

## Acknowledgement

We thank Isabell Matz and Isabel Voss for assistance with the Figures. Open Access funding enabled and organized by Projekt DEAL.

## Funding

S.V.L. is supported by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation, SFB-1470-A07 and Project 536819681) and by the Deutsche Krebsstiftung (Project 70115119). K.Ste. is supported by grants from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme (MODVASC, grant agreement No 759248), the German Research Foundation DFG (CRC1366 C07, project number 394046768), the Health+Life Science Alliance Heidelberg Mannheim GmbH and the Biotechnology and Biological Sciences Research Council (BBSRC) of the UK Research and Innovation (UKRI). M.G. is supported by the European Research Council (ERC) Advanced Grant 787971 'CuRE'; British Heart Foundation (BHF) Programme Grant RG/19/11/34633; King's College London BHF Centre of Research Excellence grant RE/18/2/34213; grants 825670 'CardioReGenix' and 874764 'REANIMA' from the European Commission Horizon 2020 programme; grant 20CVD04 from Fondation Leducq. A.C. is supported by the British Heart Foundation (FS/CRTF/21/24175). L.C. is supported by grants from the Leducq Foundation (20CVD01), the German Centre for Cardiovascular Research (DZHK) and the German Ministry of Research Education (BMBF). A.G. is supported by the Instituto de Salud Carlos III (Spain) (CIBERCV CB16/11/00483 and PI21/00946 co-financed by FEDER funds). KHH is funded by the Norwegian Research council #309762 ProCardio. LRL is supported by a NIH (National Institutes of Health Research) award. P.M. is supported by the German Center for Cardiovascular Research (DZHK; project 81Z0500101 and 81X2500195). HS is funded

by DigiMed Bayern ([www.digimed-bayern.de](http://www.digimed-bayern.de); DMB-1805-0001) from the Bavarian State Ministry of Health, by a DHM-MSRM Joint Research Center (1530/891 02) from the Bavarian State Ministry of Science and the Arts, the German Research Foundation (DFG) as part of the Sonderforschungsbereich SFB 1123 (B02) and the Sonderforschungsbereich SFB TRR 267 (B05), the German Federal Ministry of Economics and Energy in its scheme of ModulMax (Grant No: ZF4590201BA8) and the German Federal Ministry of Education and Research (BMBF) within the framework of COMMITMENT (01ZX1904A). He is a Co-applicant of the British Heart Foundation (BHF)/German Centre of Cardiovascular Research (DZHK)-collaboration (DZHK-BHF: 81X2600522) and the Leducq Foundation for Cardiovascular Research (PlaqOmics: 18CVD02). K.S.B. is supported by the DFG (Project number 471241922; RTG2824-RP4 to KSB) and the DZHK. T.T. is supported by the ERC Advanced Grant REVERSE and the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) – SFB-1470 (SFB-1470-B07). C.G.T. is supported by two grants from the Italian Ministry of Health (PNRR-MAD-2022-12376632 and RF-2016-02362988). C.T. is supported by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) – SFB-1470 (SFB-1470-B02). P.v.d.M. is supported by a grant from the European Research Council (ERC CoG 101045236, DISSECT-HF). E.V.R. is supported by the Dutch Cardiovascular Alliance CVON Arena-PRIME 2017-18 and a Leducq Foundation grant (20CVD04). European Union Commission's Seventh Framework programme IMI2-CARDIATEAM — N° 821508 and SH receives support of IMI2-CARDIATEAM, from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement N° 821508; the JU receives support from the European Union's Horizon 2020 research and innovation programme. Netherlands Cardiovascular Research Initiative, an initiative with support of the Dutch Heart Foundation, 2017-18, Double Dosis, 2020-B005.

**Conflict of interest:** M.G. is scientific founder, consultant, member of the Board and equity holder in Purespring Therapeutics, Forcefield Therapeutics and Heqet Therapeutics. L.C. is a member of DiNAQOR Scientific Advisory Board and has shares in DiNAQOR. P.G.P. reports speaker fees from BMS, Pfizer, Bridgebio, Ionis Pharmaceuticals, AstraZeneca, NovoNordisk, Intellia and Alnylam Pharmaceuticals, consulting fees from BMS, Cytokinetics, Rocket Pharmaceuticals, Lexeo, Pfizer, Bridgebio, Daiichi Sankyo, Neuroimmune, Alnylam Pharmaceuticals, AstraZeneca, NovoNordisk, ATTRalus, Intellia, Idovent, General Electric and Alexion, and research/educational support to its institution from Pfizer, Bridgebio, NovoNordisk, AstraZeneca, Intellia and Alnylam Pharmaceuticals. L.R.L. reports speaker fees from BMS, Sanofi, and Alnylam, consulting fees from Novo Nordisk and BMS, and received a research grant from BMS. P.M. is co-founder, shareholder and CEO of AaviGen GmbH. K.S.B. received research support from Novartis and BionTECH and speaker's honoraria from Novartis. H.S. received consultancy fees from Novartis, Pharmacosmos, AstraZeneca, Daiichi Sankyo, Bayer, Boehringer Ingelheim. T.T. filed and licensed patents in the field of non-coding RNA based therapeutics; is founder and shareholder of Cardiopharmaceuticals GmbH; received personal fees for lectures and/or scientific advice from Bayer, Boehringer Ingelheim, Novo Nordisk, Sanofi-Aventis, Takeda, Amicus Therapeutics. C.G.T. reports honoraria or consultation fees from VivaLyfe, Univers Formazione, Solaris, Summeet, AstraZeneca, Myocardial Solutions, Medtronic; funding from Amgen and MSD; listed as an inventor of two patents related to heart failure, outside the submitted work. C.T. has received speaker fees and/or contributions to congresses from Abbott, Abiomed, AstraZeneca, Bayer, Berlin Chemie, Novartis, Pfizer, and Servier; all outside the submitted work. The UMCG, which employs P.v.d.M., received consultancy fees and/or grants from Novartis, Pharmacosmos, Vifor Pharma, AstraZeneca, Pfizer, Pharma Nord, BridgeBio, Novo Nordisk, Daiichi Sankyo, Boehringer Ingelheim and Ionis. E.V.R. is a founder of Phlox Therapeutics and Revier Therapeutics and a scientific advisor for Heartbeat.Bio and

Tenaya Therapeutics. M.M. received consultancy honoraria from Abbott Structural heart, AstraZeneca, Bayer, Boehringer Ingelheim, Edwards lifeSciences, Novo Nordisk, Roche diagnostics. S.H. receives personal fees for independent scientific advice on early development in the field of heart failure for AstraZeneca, Ribocure, and CSL Behring, and receives research support from AstraZeneca and CSL Behring. All other authors have nothing to disclose.

## References

- Friedmann T, Roblin R. Gene therapy for human genetic disease? *Science* 1972;175:949–955. <https://doi.org/10.1126/science.175.4025.949>
- Liu N, Olson EN. CRISPR modeling and correction of cardiovascular disease. *Circ Res* 2022;130:1827–1850. <https://doi.org/10.1161/CIRCRESAHA.122.320496>
- van Rooij E, Olson EN. MicroRNA therapeutics for cardiovascular disease: Opportunities and obstacles. *Nat Rev Drug Discov* 2012;11:860–872. <https://doi.org/10.1038/nrd3864>
- Giacca M. Fulfilling the promise of RNA therapies for cardiac repair and regeneration. *Stem Cells Transl Med* 2023;12:527–535. <https://doi.org/10.1093/scctm/szad038>
- Shah AM, Giacca M. Small non-coding RNA therapeutics for cardiovascular disease. *Eur Heart J* 2022;43:4548–4561. <https://doi.org/10.1093/eurheartj/ehac463>
- Wang D, Tai PWL, Gao G. Adeno-associated virus vector as a platform for gene therapy delivery. *Nat Rev Drug Discov* 2019;18:358–378. <https://doi.org/10.1038/s41573-019-0012-9>
- Kulkarni JA, Cullis PR, van der Meel R. Lipid nanoparticles enabling gene therapies: From concepts to clinical utility. *Nucleic Acid Ther* 2018;28:146–157. <https://doi.org/10.1089/nat.2018.0721>
- Raal FJ, Kallend D, Ray KK, Turner T, Koenig W, Wright RS, et al. ORION-9 Investigators. Inclisiran for the treatment of heterozygous familial hypercholesterolemia. *N Engl J Med* 2020;382:1520–1530. <https://doi.org/10.1056/NEJMoa1913805>
- Amor-Salamanca A, Castillo S, Gonzalez-Vioque E, Dominguez F, Quintana L, Lluís-Ganella C, et al. Genetically confirmed familial hypercholesterolemia in patients with acute coronary syndrome. *J Am Coll Cardiol* 2017;70:1732–1740. <https://doi.org/10.1016/j.jacc.2017.08.009>
- Desai AS, Webb DJ, Taubel J, Casey S, Cheng Y, Robbie GJ, et al. Zilebesiran, an RNA interference therapeutic agent for hypertension. *N Engl J Med* 2023;389:228–238. <https://doi.org/10.1056/NEJMoa2208391>
- O'Donoghue ML, Rosenson RS, Gencer B, Lopez JAG, Lepor NE, Baum SJ, et al. OCEAN(a)-DOSE Trial Investigators. Small interfering RNA to reduce lipoprotein(a) in cardiovascular disease. *N Engl J Med* 2022;387:1855–1864. <https://doi.org/10.1056/NEJMoa2211023>
- Gillmore JD, Gane E, Taubel J, Kao J, Fontana M, Maitland ML, et al. CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. *N Engl J Med* 2021;385:493–502. <https://doi.org/10.1056/NEJMoa2107454>
- Jaski BE, Jessup ML, Mancini DM, Cappola TP, Pauly DF, Greenberg B, et al. Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID) trial, a first-in-human phase 1/2 clinical trial. *J Card Fail* 2009;15:171–181. <https://doi.org/10.1016/j.cardfail.2009.01.013>
- Jessup M, Greenberg B, Mancini D, Cappola T, Pauly DF, Jaski B, et al. Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): A phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca<sup>2+</sup>-ATPase in patients with advanced heart failure. *Circulation* 2011;124:304–313. <https://doi.org/10.1161/CIRCULATIONAHA.111.022889>
- Hulot JS, Salem JE, Redheuil A, Collet JP, Varnous S, Jourdain P, et al. Effect of intracoronary administration of AAV1/SERCA2a on ventricular remodelling in patients with advanced systolic heart failure: Results from the AGENT-HF randomized phase 2 trial. *Eur J Heart Fail* 2017;19:1534–1541. <https://doi.org/10.1002/ehf.826>
- Watts JK, Corey DR. Silencing disease genes in the laboratory and the clinic. *J Pathol* 2012;226:365–379. <https://doi.org/10.1002/path.2993>
- Lennox KA, Behlke MA. Chemical modification and design of anti-miRNA oligonucleotides. *Gene Ther* 2011;18:1111–1120. <https://doi.org/10.1038/gt.2011.100>
- Dhuri K, Bechtold C, Quijano E, Pham H, Gupta A, Vikram A, et al. Antisense oligonucleotides: An emerging area in drug discovery and development. *J Clin Med* 2020;9:2004. <https://doi.org/10.3390/jcm9062004>
- Beermann J, Piccoli MT, Viereck J, Thum T. Non-coding RNAs in development and disease: Background, mechanisms, and therapeutic approaches. *Physiol Rev* 2016;96:1297–1325. <https://doi.org/10.1152/physrev.00041.2015>
- Devaux Y, Badimon L. CDR132L: Another brick in the wall towards the use of miRNAs to treat cardiovascular disease. *Eur Heart J* 2021;42:202–204. <https://doi.org/10.1093/eurheartj/ehaa870>
- Lesizza P, Prosdocimo G, Martinelli V, Sinagra G, Zacchigna S, Giacca M. Single-dose intracardiac injection of pro-regenerative microRNAs improves cardiac function after myocardial infarction. *Circ Res* 2017;120:1298–1304. <https://doi.org/10.1161/CIRCRESAHA.116.309589>
- Gao F, Kataoka M, Liu N, Liang T, Huang ZP, Gu F, et al. Therapeutic role of miR-19a/19b in cardiac regeneration and protection from myocardial infarction. *Nat Commun* 2019;10:1802. <https://doi.org/10.1038/s41467-019-09530-1>
- Tian Y, Liu Y, Wang T, Zhou N, Kong J, Chen L, et al. A microRNA-Hippo pathway that promotes cardiomyocyte proliferation and cardiac regeneration in mice. *Sci Transl Med* 2015;7:279ra238. <https://doi.org/10.1126/scitranslmed.3010841>
- Deng S, Zhao Q, Zhen L, Zhang C, Liu C, Wang G, et al. Neonatal heart-enriched miR-708 promotes proliferation and stress resistance of cardiomyocytes in rodents. *Theranostics* 2017;7:1953–1965. <https://doi.org/10.7150/thno.16478>
- Kariko K, Muramatsu H, Welsh FA, Ludwig J, Kato H, Akira S, et al. Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. *Mol Ther* 2008;16:1833–1840. <https://doi.org/10.1038/mt.2008.200>
- Henderson JM, Ujita A, Hill E, Yousif-Rosales S, Smith C, Ko N, et al. Cap 1 messenger RNA synthesis with co-transcriptional CleanCap<sup>®</sup> analog by in vitro transcription. *Curr Protoc* 2021;1:e39. <https://doi.org/10.1002/cpz1.139>
- Sahin U, Kariko K, Tureci O. mRNA-based therapeutics – developing a new class of drugs. *Nat Rev Drug Discov* 2014;13:759–780. <https://doi.org/10.1038/nrd4278>
- Chen Q, Zhang Y, Yin H. Recent advances in chemical modifications of guide RNA, mRNA and donor template for CRISPR-mediated genome editing. *Adv Drug Deliv Rev* 2021;168:246–258. <https://doi.org/10.1016/j.addr.2020.10.014>
- Magadam A. Modified mRNA therapeutics for heart diseases. *Int J Mol Sci* 2022;23:15514. <https://doi.org/10.3390/ijms232415514>
- Magadam A, Kaur K, Zangi L. mRNA-based protein replacement therapy for the heart. *Mol Ther* 2019;27:785–793. <https://doi.org/10.1016/j.yjth.2018.11.018>
- Kaur K, Zangi L. Modified mRNA as a therapeutic tool for the heart. *Cardiovasc Drugs Ther* 2020;34:871–880. <https://doi.org/10.1007/s10557-020-07051-4>
- Magadam A, Singh N, Kurian AA, Sharkar MTK, Chepurko E, Zangi L. Ablation of a single N-glycosylation site in human FSTL 1 induces cardiomyocyte proliferation and cardiac regeneration. *Mol Ther Nucleic Acids* 2018;13:133–143. <https://doi.org/10.1016/j.omtn.2018.08.021>
- Magadam A, Singh N, Kurian AA, Munir I, Mehmood T, Brown K, et al. Pkm2 regulates cardiomyocyte cell cycle and promotes cardiac regeneration. *Circulation* 2020;141:1249–1265. <https://doi.org/10.1161/CIRCULATIONAHA.119.043067>
- Chen J, Ma Q, King JS, Sun Y, Xu B, Zhang X, et al. aYAP modRNA reduces cardiac inflammation and hypertrophy in a murine ischemia-reperfusion model. *Life Sci Alliance* 2020;3:e201900424. <https://doi.org/10.26508/lsa.201900424>
- Hadas Y, Vincek AS, Youssef E, Zak MM, Chepurko E, Sultana N, et al. Altering sphingolipid metabolism attenuates cell death and inflammatory response after myocardial infarction. *Circulation* 2020;141:916–930. <https://doi.org/10.1161/CIRCULATIONAHA.119.041882>
- Huang CL, Leblond AL, Turner EC, Kumar AH, Martin K, Whelan D, et al. Synthetic chemically modified mRNA-based delivery of cytoprotective factor promotes early cardiomyocyte survival post-acute myocardial infarction. *Mol Pharm* 2015;12:991–996. <https://doi.org/10.1021/mp5006239>
- Zangi L, Lui KO, von Gise A, Ma Q, Ebina W, Ptaszek LM, et al. Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction. *Nat Biotechnol* 2013;31:898–907. <https://doi.org/10.1038/nbt.2682>
- Carlsson L, Clarke JC, Yen C, Gregoire F, Alberly T, Billger M, et al. Biocompatible, purified VEGF-A mRNA improves cardiac function after intracardiac injection 1 week post-myocardial infarction in swine. *Mol Ther Methods Clin Dev* 2018;9:330–346. <https://doi.org/10.1016/j.omtm.2018.04.003>
- Rurik JG, Tombacz I, Yadegari A, Mendez Fernandez PO, Shewale SV, Li L, et al. CAR T cells produced in vivo to treat cardiac injury. *Science* 2022;375:91–96. <https://doi.org/10.1126/science.abm0594>
- Crooke ST, Wang S, Vickers TA, Shen W, Liang XH. Cellular uptake and trafficking of antisense oligonucleotides. *Nat Biotechnol* 2017;35:230–237. <https://doi.org/10.1038/nbt.3779>
- Springer AD, Dowdy SF. GalNAc-siRNA conjugates: leading the way for delivery of RNAi therapeutics. *Nucleic Acid Ther* 2018;28:109–118. <https://doi.org/10.1089/nat.2018.0736>

42. MacLachlan I, Cullis P, Graham RW. Progress towards a synthetic virus for systemic gene therapy. *Curr Opin Mol Ther* 1999;1:252–259.
43. Heyes J, Palmer L, Bremner K, MacLachlan I. Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids. *J Control Release* 2005;107:276–287. <https://doi.org/10.1016/j.jconrel.2005.06.014>
44. Grimm D, Buning H. Small but increasingly mighty: Latest advances in AAV vector research, design, and evolution. *Hum Gene Ther* 2017;28:1075–1086. <https://doi.org/10.1089/hum.2017.172>
45. Muller OJ, Kaul F, Weitzman MD, Pasqualini R, Arap W, Kleinschmidt JA, et al. Random peptide libraries displayed on adeno-associated virus to select for targeted gene therapy vectors. *Nat Biotechnol* 2003;21:1040–1046. <https://doi.org/10.1038/nbt856>
46. Varadi K, Michelfelder S, Korff T, Hecker M, Trepel M, Katus HA, et al. Novel random peptide libraries displayed on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors. *Gene Ther* 2012;19:800–809. <https://doi.org/10.1038/gt.2011.143>
47. Groß S, Rode L, Biß S, Riedel I, Gietz A, Bär C, et al. Engineered adeno-associated viral vectors with an improved in vivo targeting of cardiac fibroblasts. *Eur J Heart Fail* 2023;25:441.
48. Francisco J, Zhang Y, Nakada Y, Jeong JI, Huang CY, Ivessa A, et al. AAV-mediated YAP expression in cardiac fibroblasts promotes inflammation and increases fibrosis. *Sci Rep* 2021;11:10553. <https://doi.org/10.1038/s41598-021-89989-5>
49. Pesce M, Duda GN, Forte G, Girao H, Raya A, Roca-Cusachs P, et al. Cardiac fibroblasts and mechanosensation in heart development, health and disease. *Nat Rev Cardiol* 2023;20:309–324. <https://doi.org/10.1038/s41569-022-00799-2>
50. Konkalmatt PR, Beyers RJ, O'Connor DM, Xu Y, Seaman ME, French BA. Cardiac-selective expression of extracellular superoxide dismutase after systemic injection of adeno-associated virus 9 protects the heart against post-myocardial infarction left ventricular remodeling. *Circ Cardiovasc Imaging* 2013;6:478–486. <https://doi.org/10.1161/CIRCIMAGING.112.000320>
51. Korhonen J, Lahtinen I, Halmekyto M, Alhonen L, Janne J, Dumont D, et al. Endothelial-specific gene expression directed by the tie gene promoter in vivo. *Blood* 1995;86:1828–1835.
52. Komor AC, Kim YB, Packer MS, Zuris JA, Liu DR. Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. *Nature* 2016;533:420–424. <https://doi.org/10.1038/nature17946>
53. Rees HA, Liu DR. Base editing: precision chemistry on the genome and transcriptome of living cells. *Nat Rev Genet* 2018;19:770–788. <https://doi.org/10.1038/s41576-018-0059-1>
54. Lebek S, Chemello F, Caravia XM, Tan W, Li H, Chen K, et al. Ablation of CaMKII $\delta$  oxidation by CRISPR-Cas9 base editing as a therapy for cardiac disease. *Science* 2023;379:179–185. <https://doi.org/10.1126/science.ade1105>
55. Adams D, Gonzalez-Duarte A, O'Riordan WD, Yang CC, Ueda M, Kristen AV, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. *N Engl J Med* 2018;379:11–21. <https://doi.org/10.1056/NEJMoa1716153>
56. Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A, et al. Diagnosis and treatment of cardiac amyloidosis: A position statement of the ESC Working Group on Myocardial and Pericardial Diseases. *Eur Heart J* 2021;42:1554–1568. <https://doi.org/10.1093/eurheartj/ehab072>
57. Coelho T, Adams D, Silva A, Lozeron P, Hawkins PN, Mant T, et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. *N Engl J Med* 2013;369:819–829. <https://doi.org/10.1056/NEJMoa1208760>
58. Rosenblum HR, Griffin JM, Minamisawa M, Prasad N, Vest J, White MT, et al. Effect of patisiran on stroke volume in hereditary transthyretin-mediated amyloidosis: Insights from pressure-volume analysis of the APOLLO study. *Eur J Heart Fail* 2023;25:727–736. <https://doi.org/10.1002/ehfj.2783>
59. Solomon SD, Adams D, Kristen A, Grogan M, Gonzalez-Duarte A, Maurer MS, et al. Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis. *Circulation* 2019;139:431–443. <https://doi.org/10.1161/CIRCULATIONAHA.118.035831>
60. Maurer MS, Kale P, Fontana M, Berk JL, Grogan M, Gustafsson F, et al.; APOLLO-B Trial Investigators. Patisiran treatment in patients with transthyretin cardiac amyloidosis. *N Engl J Med* 2023;389:1553–1565. <https://doi.org/10.1056/NEJMoa2300757>
61. Adams D, Tourneville IL, Taylor MS, Coelho T, Plante-Bordeneuve V, Berk JL, et al.; HELIOS-A Collaborators. Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: A randomized clinical trial. *Amyloid* 2023;30:1–9. <https://doi.org/10.1080/13506129.2022.2091985>
62. Garcia-Pavia P, Grogan M, Kale P, Berk JL, Maurer MS, Conceicao I, et al. Impact of vutrisiran on exploratory cardiac parameters in hereditary transthyretin-mediated amyloidosis with polyneuropathy. *Eur J Heart Fail* 2024;26:397–410. <https://doi.org/10.1002/ehfj.3138>
63. Fontana M, Berk JL, Gillmore JD, Wittes RM, Grogan M, Drachman B, et al.; HELIO-B Trial Investigators. Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy. *N Engl J Med* 2024. <https://doi.org/10.1056/NEJMoa2409134> Published online ahead of print 30/08/24.
64. Ray KK, Wright RS, Kallend D, Koenig W, Leiter LA, Raal FJ, et al.; ORION-10 and ORION-11 Investigators. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. *N Engl J Med* 2020;382:1507–1519. <https://doi.org/10.1056/NEJMoa1912387>
65. Ray KK, Raal FJ, Kallend DG, Jaros MJ, Koenig W, Leiter LA, et al. Inclisiran and cardiovascular events: A patient-level analysis of phase III trials. *Eur Heart J* 2023;44:129–138. <https://doi.org/10.1093/eurheartj/ehac594>
66. Stitzel NO, Khera AV, Wang X, Bierhals AJ, Vourakis AC, Sperry AE, et al. ANGPTL3 deficiency and protection against coronary artery disease. *J Am Coll Cardiol* 2017;69:2054–2063. <https://doi.org/10.1016/j.jacc.2017.02.030>
67. Watts GF, Scott R, Gladding P, Sullivan D, Baker J, Clifton P, et al. Pharmacodynamic effect of ARO-ANG3, an investigational RNA interference targeting hepatic angiotensin-like protein 3, in patients with hypercholesterolemia. *Circulation* 2020;142:A15751. doi:10.1161/circ.142.suppl\_3.15751
68. Emerging Risk Factors C, Erqou S, Kaptoge S, Perry PL, Di Angelantonio E, Thompson A, et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. *JAMA* 2009;302:412–423. <https://doi.org/10.1001/jama.2009.1063>
69. Addison ML, Ranasinghe P, Webb DJ. Emerging insights and future prospects for therapeutic application of siRNA targeting angiotensinogen in hypertension. *Expert Rev Clin Pharmacol* 2023;16:1025–1033. <https://doi.org/10.1080/17512433.2023.2277330>
70. Benson MD, Waddington-Cruz M, Berk JL, Polydefkis M, Dyck PJ, Wang AK, et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. *N Engl J Med* 2018;379:22–31. <https://doi.org/10.1056/NEJMoa1716793>
71. Dasgupta NR, Rissing SM, Smith J, Jung J, Benson MD. Inotersen therapy of transthyretin amyloid cardiomyopathy. *Amyloid* 2020;27:52–58. <https://doi.org/10.1080/13506129.2019.1685487>
72. Coelho T, Marques W Jr, Dasgupta NR, Chao CC, Parman Y, Franca MC Jr, et al.; NEURO-TTRransform Investigators. Eplontersen for hereditary transthyretin amyloidosis with polyneuropathy. *JAMA* 2023;330:1448–1458. <https://doi.org/10.1001/jama.2023.18688>
73. Masri A, Maurer MS, Claggett BL, Kulac I, Waddington Cruz M, Conceicao I, et al. Effect of eplontersen on cardiac structure and function in patients with hereditary transthyretin amyloidosis. *J Card Fail* 2024;30:973–980. <https://doi.org/10.1016/j.cardfail.2023.11.016>
74. Lagerbauer B, Engelhardt S. MicroRNAs as therapeutic targets in cardiovascular disease. *J Clin Invest* 2022;132:e159179. <https://doi.org/10.1172/JCI159179>
75. Huang CK, Kafert-Kasting S, Thum T. Preclinical and clinical development of noncoding RNA therapeutics for cardiovascular disease. *Circ Res* 2020;126:663–678. <https://doi.org/10.1161/CIRCRESAHA.119.315856>
76. Ucar A, Gupta SK, Fiedler J, Eriki E, Kardasinski M, Batkai S, et al. The miRNA-212/132 family regulates both cardiac hypertrophy and cardiomyocyte autophagy. *Nat Commun* 2012;3:1078. <https://doi.org/10.1038/ncomms2090>
77. Foinquinos A, Batkai S, Genschel C, Viereck J, Rump S, Gyongyosi M, et al. Preclinical development of a miR-132 inhibitor for heart failure treatment. *Nat Commun* 2020;11:633. <https://doi.org/10.1038/s41467-020-14349-2>
78. Batkai S, Genschel C, Viereck J, Rump S, Bar C, Borchert T, et al. CDR132L improves systolic and diastolic function in a large animal model of chronic heart failure. *Eur Heart J* 2021;42:192–201. <https://doi.org/10.1093/eurheartj/ehaa791>
79. Taubel J, Hauke W, Rump S, Viereck J, Batkai S, Poetzsch J, et al. Novel antisense therapy targeting microRNA-132 in patients with heart failure: Results of a first-in-human Phase 1b randomized, double-blind, placebo-controlled study. *Eur Heart J* 2021;42:178–188. <https://doi.org/10.1093/eurheartj/ehaa898>
80. Bauersachs J, Solomon SD, Anker SD, Antorrena-Miranda I, Batkai S, Viereck J, et al. Efficacy and safety of CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: Rationale and design of the HF-REVERT trial. *Eur J Heart Fail* 2024;26:674–682. <https://doi.org/10.1002/ehfj.3139>
81. Collen A, Bergenhem N, Carlsson L, Chien KR, Hoge S, Gan LM, et al. VEGF mRNA for regenerative treatment of heart failure. *Nat Rev Drug Discov* 2022;21:79–80. <https://doi.org/10.1038/s41573-021-00355-6>
82. Gan LM, Lagerstrom-Fermer M, Carlsson LG, Arfvidsson C, Egnell AC, Rudvik A, et al. Intradermal delivery of modified mRNA encoding VEGF-A in patients with type 2 diabetes. *Nat Commun* 2019;10:871. <https://doi.org/10.1038/s41467-019-08852-4>
83. Anttila V, Saraste A, Knuuti J, Hedman M, Jaakkola P, Laugwitz KL, et al. Direct intramyocardial injection of VEGF mRNA in patients undergoing coronary artery bypass grafting. *Mol Ther* 2023;31:866–874. <https://doi.org/10.1016/j.ymthe.2022.11.017>

84. Kranias EG, Hajjar RJ. Modulation of cardiac contractility by the phospholamban/SERCA2a regulatome. *Circ Res* 2012;110:1646–1660. <https://doi.org/10.1161/CIRCRESAHA.111.259754>
85. Greenberg B, Butler J, Felker GM, Ponikowski P, Voors AA, Desai AS, et al. Calcium Upregulation by Percutaneous Administration of Gene Therapy in Patients with Cardiac Disease (CUPID 2): A randomised, multinational, double-blind, placebo-controlled, phase 2b trial. *Lancet* 2016;387:1178–1186. [https://doi.org/10.1016/S0140-6736\(16\)00082-9](https://doi.org/10.1016/S0140-6736(16)00082-9)
86. Cannata A, Ali H, Sinagra G, Giacca M. Gene therapy for the heart lessons learned and future perspectives. *Circ Res* 2020;126:1394–1414. <https://doi.org/10.1161/CIRCRESAHA.120.315855>
87. Ragone I, Barallobre-Barreiro J, Takov K, Theofilatos K, Yin X, Schmidt LE, et al. SERCA2a protein levels are unaltered in human heart failure. *Circulation* 2023;148:613–616. <https://doi.org/10.1161/CIRCULATIONAHA.123.064513>
88. Lyon AR, Babalis D, Morley-Smith AC, Hedger M, Suarez Barrientos A, Faldes G, et al. Investigation of the safety and feasibility of AAV1/SERCA2a gene transfer in patients with chronic heart failure supported with a left ventricular assist device – the SERCA-LVAD trial. *Gene Ther* 2020;27:579–590. <https://doi.org/10.1038/s41434-020-0171-7>
89. Ishikawa K, Fish KM, Tilemann L, Rapti K, Agüero J, Santos-Gallego CG, et al. Cardiac I-1c overexpression with reengineered AAV improves cardiac function in swine ischemic heart failure. *Mol Ther* 2014;22:2038–2045. <https://doi.org/10.1038/mt.2014.127>
90. Pathak A, del Monte F, Zhao W, Schultz JE, Lorenz JN, Bodi I, et al. Enhancement of cardiac function and suppression of heart failure progression by inhibition of protein phosphatase 1. *Circ Res* 2005;96:756–766. <https://doi.org/10.1161/01.RES.0000161256.85833.f>
91. Jagadisan B, Dhawan A. Adeno-associated viral vector gene therapy: Challenges for the paediatric hepatologist. *J Pediatr Gastroenterol Nutr* 2024;79:485–494. <https://doi.org/10.1002/jpn3.12326>
92. Wong C. UK first to approve CRISPR treatment for diseases: What you need to know. *Nature* 2023;623:676–677. <https://doi.org/10.1038/d41586-023-03590-6>
93. Gertz MA, Benson MD, Dyck PJ, Grogan M, Coelho T, Cruz M, et al. Diagnosis, prognosis, and therapy of transthyretin amyloidosis. *J Am Coll Cardiol* 2015;66:2451–2466. <https://doi.org/10.1016/j.jacc.2015.09.075>
94. Carvalho T. CRISPR-Cas9 hits its target in amyloidosis. *Nat Med* 2022;28:2438. <https://doi.org/10.1038/d41591-022-00101-4>
95. Rothgangl T, Dennis MK, Lin PJC, Oka R, Witzigmann D, Villiger L, et al. In vivo adenine base editing of PCSK9 in macaques reduces LDL cholesterol levels. *Nat Biotechnol* 2021;39:949–957. <https://doi.org/10.1038/s41587-021-00933-4>
96. Musunuru K, Chadwick AC, Mizoguchi T, Garcia SP, DeNizio JE, Reiss CV, et al. In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates. *Nature* 2021;593:429–434. <https://doi.org/10.1038/s41586-021-03534-y>
97. Seferovic PM, Polovina M, Bauersachs J, Arad M, Ben Gal T, Lund LH, et al. Heart failure in cardiomyopathies: A position paper from the Heart Failure Association of the European Society of Cardiology. *Eur J Heart Fail* 2019;21:553–576. <https://doi.org/10.1002/ehfj.1461>
98. Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: The Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). *Eur Heart J* 2014;35:2733–2779. <https://doi.org/10.1093/eurheartj/ehu284>
99. Heymans S, Lakdawala NK, Tschope C, Klingel K. Dilated cardiomyopathy: Causes, mechanisms, and current and future treatment approaches. *Lancet* 2023;402:998–1011. [https://doi.org/10.1016/S0140-6736\(23\)01241-2](https://doi.org/10.1016/S0140-6736(23)01241-2)
100. Arbelo E, Protonotarios A, Gimeno JR, Arbustini E, Barriales-Villa R, Basso C, et al. 2023 ESC Guidelines for the management of cardiomyopathies. *Eur Heart J* 2023;44:3503–3626. <https://doi.org/10.1093/eurheartj/ehad194>
101. Olivetto I, Oreziak A, Barriales-Villa R, Abraham TP, Masri A, Garcia-Pavia P, et al.; EXPLORER-HCM Study Investigators. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): A randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet* 2020;396:759–769. [https://doi.org/10.1016/S0140-6736\(20\)31792-X](https://doi.org/10.1016/S0140-6736(20)31792-X)
102. Grote Beverborg N, Spater D, Knoll R, Hidalgo A, Yeh ST, Elbeck Z, et al. Phospholamban antisense oligonucleotides improve cardiac function in murine cardiomyopathy. *Nat Commun* 2021;12:5180. <https://doi.org/10.1038/s41467-021-25439-0>
103. Eijgenraam TR, Stege NM, Oliveira Nunes Teixeira V, de Brouwer R, Schouten EM, Grote Beverborg N, et al. Antisense therapy attenuates phospholamban p.(Arg14del) cardiomyopathy in mice and reverses protein aggregation. *Int J Mol Sci* 2022;23:2427. <https://doi.org/10.3390/ijms23052427>
104. Geddicke-Hornung C, Behrens-Gawlik V, Reischmann S, Geertz B, Stimpel D, Weinberger F, et al. Rescue of cardiomyopathy through U7snRNA-mediated exon skipping in Mybpc3-targeted knock-in mice. *EMBO Mol Med* 2013;5:1128–1145. <https://doi.org/10.1002/emmm.201202168>
105. Jiang J, Wakimoto H, Seidman JG, Seidman CE. Allele-specific silencing of mutant Myh6 transcripts in mice suppresses hypertrophic cardiomyopathy. *Science* 2013;342:111–114. <https://doi.org/10.1126/science.1236921>
106. Carrier L, Schlossarek S, Willis MS, Eschenhagen T. The ubiquitin-proteasome system and nonsense-mediated mRNA decay in hypertrophic cardiomyopathy. *Cardiovasc Res* 2010;85:330–338. <https://doi.org/10.1093/cvr/cvp247>
107. Vignier N, Schlossarek S, Frayse B, Mearini G, Kramer E, Pointu H, et al. Nonsense-mediated mRNA decay and ubiquitin-proteasome system regulate cardiac myosin-binding protein C mutant levels in cardiomyopathic mice. *Circ Res* 2009;105:239–248. <https://doi.org/10.1161/CIRCRESAHA.109.201251>
108. Carrier L. Targeting the population for gene therapy with MYBPC3. *J Mol Cell Cardiol* 2021;150:101–108. <https://doi.org/10.1016/j.yjmcc.2020.10.003>
109. Herman DS, Lam L, Taylor MR, Wang L, Teekakirikul P, Christodoulou D, et al. Truncations of titin causing dilated cardiomyopathy. *N Engl J Med* 2012;366:619–628. <https://doi.org/10.1056/NEJMoa1110186>
110. Qu HQ, Feldman AM, Hakonarson H. Genetics of BAG3: A paradigm for developing precision therapies for dilated cardiomyopathies. *J Am Heart Assoc* 2022;11:e027373. <https://doi.org/10.1161/JAHA.122.027373>
111. Verdonschot JAJ, Vanhoutte EK, Claes GRF, Helderman-van den Enden A, Hoeljmakers JGJ, Hellebrekers D, et al. A mutation update for the FLNC gene in myopathies and cardiomyopathies. *Hum Mutat* 2020;41:1091–1111. <https://doi.org/10.1002/humu.24004>
112. Hoorntje ET, Burns C, Marsili L, Corden B, Parikh VN, Te Meerman GJ, et al. Variant location is a novel risk factor for individuals with arrhythmogenic cardiomyopathy due to a desmoplakin (DSP) truncating variant. *Circ Genom Precis Med* 2023;16:e003672. <https://doi.org/10.1161/CIRCGEN.121.003672>
113. Dries AM, Kirillova A, Reuter CM, Garcia J, Zouk H, Hawley M, et al. The genetic architecture of plakophilin 2 cardiomyopathy. *Genet Med* 2021;23:1961–1968. <https://doi.org/10.1038/s41436-021-01233-7>
114. Mearini G, Stimpel D, Geertz B, Weinberger F, Kramer E, Schlossarek S, et al. Mybpc3 gene therapy for neonatal cardiomyopathy enables long-term disease prevention in mice. *Nat Commun* 2014;5:5515. <https://doi.org/10.1038/ncomms6515>
115. Prondzynski M, Kramer E, Laufer SD, Shibamiya A, Pless O, Flenner F, et al. Evaluation of MYBPC3 trans-splicing and gene replacement as therapeutic options in human iPSC-derived cardiomyocytes. *Mol Ther Nucleic Acids* 2017;7:475–486. <https://doi.org/10.1016/j.omtn.2017.05.008>
116. Bradford WH, Zhang J, Gutierrez-Lara EJ, Liang Y, Do A, Wang TM, et al. Plakophilin 2 gene therapy prevents and rescues arrhythmogenic right ventricular cardiomyopathy in a mouse model harboring patient genetics. *Nat Cardiovasc Res* 2023;2:1246–1261. <https://doi.org/10.1038/s44161-023-00370-3>
117. Taylor MRG, Adler ED. Danon Disease. In: Adam MP, Feldman J, Mirzaz GM, Pagon RA, Wallace SE, Bean LJH, et al., eds. *GeneReviews*®. Seattle, WA: University of Washington; 1993.
118. Koblan LW, Erdos MR, Wilson C, Cabral WA, Levy JM, Xiong ZM, et al. In vivo base editing rescues Hutchinson-Gilford progeria syndrome in mice. *Nature* 2021;589:608–614. <https://doi.org/10.1038/s41586-020-03086-7>
119. Nishiyama Z, Zhang Y, Cui M, Li H, Sanchez-Ortiz E, McAnally JR, et al. Precise genomic editing of pathogenic mutations in RBM20 rescues dilated cardiomyopathy. *Sci Transl Med* 2022;14:eade1633. <https://doi.org/10.1126/scitranslmed.ade1633>
120. Ma S, Jiang W, Liu X, Lu WJ, Qi T, Wei J, et al. Efficient correction of a hypertrophic cardiomyopathy mutation by ABEmax-NG. *Circ Res* 2021;129:895–908. <https://doi.org/10.1161/CIRCRESAHA.120.318674>
121. Chai AC, Cui M, Chemello F, Li H, Chen K, Tan W, et al. Base editing correction of hypertrophic cardiomyopathy in human cardiomyocytes and humanized mice. *Nat Med* 2023;29:401–411. <https://doi.org/10.1038/s41591-022-02176-5>
122. Reichart D, Newby GA, Wakimoto H, Lun M, Gorham JM, Curran JJ, et al. Efficient in vivo genome editing prevents hypertrophic cardiomyopathy in mice. *Nat Med* 2023;29:412–421. <https://doi.org/10.1038/s41591-022-02190-7>
123. Chemello F, Chai AC, Li H, Rodriguez-Caycedo C, Sanchez-Ortiz E, Atmanli A, et al. Precise correction of Duchenne muscular dystrophy exon deletion mutations by base and prime editing. *Sci Adv* 2021;7:eabg4910. <https://doi.org/10.1126/sciadv.abg4910>
124. Dick E, Kalra S, Anderson D, George V, Ritso M, Laval SH, et al. Exon skipping and gene transfer restore dystrophin expression in human induced pluripotent stem cells-cardiomyocytes harboring DMD mutations. *Stem Cells Dev* 2013;22:2714–2724. <https://doi.org/10.1089/scd.2013.0135>
125. Anzalone AV, Randolph PB, Davis JR, Sousa AA, Koblan LW, Levy JM, et al. Search-and-replace genome editing without double-strand breaks or donor DNA. *Nature* 2019;576:149–157. <https://doi.org/10.1038/s41586-019-1711-4>
126. Surun D, Schneider A, Mircetic J, Neumann K, Lansing F, Paszkowski-Rogacz M, et al. Efficient generation and correction of mutations in human iPSCs utilizing

- mRNAs of CRISPR base editors and prime editors. *Genes (Basel)* 2020;**11**:511. <https://doi.org/10.3390/genes11050511>
127. Chen PJ, Hussmann JA, Yan J, Knipping F, Ravisankar P, Chen PF, et al. Enhanced prime editing systems by manipulating cellular determinants of editing outcomes. *Cell* 2021;**184**:5635–5652.e29. <https://doi.org/10.1016/j.cell.2021.09.018>
  128. Gene therapy needs a long-term approach. *Nat Med* 2021;**27**:563. <https://doi.org/10.1038/s41591-021-01333-6>
  129. Batty P, Mo AM, Hurlbut D, Ishida J, Yates B, Brown C, et al. Long-term follow-up of liver-directed, adeno-associated vector-mediated gene therapy in the canine model of hemophilia A. *Blood* 2022;**140**:2672–2683. <https://doi.org/10.1182/blood.2021014735>
  130. Hedman M, Muona K, Hedman A, Kivela A, Syvanne M, Eranen J, et al. Eight-year safety follow-up of coronary artery disease patients after local intracoronary VEGF gene transfer. *Gene Ther* 2009;**16**:629–634. <https://doi.org/10.1038/gt.2009.4>
  131. Rosengart TK, Bishawi MM, Halbreiner MS, Fakhoury M, Finnin E, Hollmann C, et al. Long-term follow-up assessment of a phase 1 trial of angiogenic gene therapy using direct intramyocardial administration of an adenoviral vector expressing the VEGF121 cDNA for the treatment of diffuse coronary artery disease. *Hum Gene Ther* 2013;**24**:203–208. <https://doi.org/10.1089/hum.2012.137>
  132. Leikas AJ, Hassinen I, Hedman A, Kivela A, Yla-Herttuala S, Hartikainen JEK. Long-term safety and efficacy of intramyocardial adenovirus-mediated VEGF-D<sup>ΔNAC</sup> gene therapy eight-year follow-up of phase I KAT301 study. *Gene Ther* 2022;**29**:289–293. <https://doi.org/10.1038/s41434-021-00295-1>
  133. Alhamadani F, Zhang K, Parikh R, Wu H, Rasmussen TP, Bahal R, et al. Adverse drug reactions and toxicity of the Food and Drug Administration-approved antisense oligonucleotide drugs. *Drug Metab Dispos* 2022;**50**:879–887. <https://doi.org/10.1124/dmd.121.000418>
  134. Thakur S, Sinhari A, Jain P, Jadhav HR. A perspective on oligonucleotide therapy: Approaches to patient customization. *Front Pharmacol* 2022;**13**:1006304. <https://doi.org/10.3389/fphar.2022.1006304>
  135. Erdl HCJ. Immunogenicity and toxicity of AAV gene therapy. *Front Immunol* 2022;**13**:975803. <https://doi.org/10.3389/fimmu.2022.975803>
  136. Chowdhury EA, Meno-Tetang G, Chang HY, Wu S, Huang HW, Jamier T, et al. Current progress and limitations of AAV mediated delivery of protein therapeutic genes and the importance of developing quantitative pharmacokinetic/pharmacodynamic (PK/PD) models. *Adv Drug Deliv Rev* 2021;**170**:214–237. <https://doi.org/10.1016/j.addr.2021.01.017>
  137. Muhuri M, Maeda Y, Ma H, Ram S, Fitzgerald KA, Tai PWV, et al. Overcoming innate immune barriers that impede AAV gene therapy vectors. *J Clin Invest* 2021;**131**:e143780. <https://doi.org/10.1172/JCI143780>
  138. Switala L, Di L, Gao H, Asase C, Klos M, Rengasamy P, et al. Engineered nanoparticles promote cardiac tropism of AAV vectors. *J Nanobiotechnology* 2024;**22**:223. <https://doi.org/10.1186/s12951-024-02485-6>
  139. Stellos K, Musunuru K. Challenges and advances of CRISPR-Cas9 genome editing in therapeutics. *Cardiovasc Res* 2019;**115**:e12–e14. <https://doi.org/10.1093/cvr/cvy300>
  140. Zhang XH, Tee LY, Wang XG, Huang QS, Yang SH. Off-target effects in CRISPR/Cas9-mediated genome engineering. *Mol Ther Nucleic Acids* 2015;**4**:e264. <https://doi.org/10.1038/mtna.2015.37>
  141. Ge W, Gou S, Zhao X, Jin Q, Zhuang Z, Zhao Y, et al. In vivo evaluation of guide-free Cas9-induced safety risks in a pig model. *Signal Transduct Target Ther* 2024;**9**:184. <https://doi.org/10.1038/s41392-024-01905-1>
  142. Doench JG, Fusi N, Sullender M, Hegde M, Vaimberg EW, Donovan KF, et al. Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. *Nat Biotechnol* 2016;**34**:184–191. <https://doi.org/10.1038/nbt.3437>
  143. Naeem M, Majeed S, Hoque MZ, Ahmad I. Latest developed strategies to minimize the off-target effects in CRISPR-Cas-mediated genome editing. *Cells* 2020;**9**:1608. <https://doi.org/10.3390/cells9071608>
  144. Chen Y, Liu X, Zhang Y, Wang H, Ying H, Liu M, et al. A self-restricted CRISPR system to reduce off-target effects. *Mol Ther* 2016;**24**:1508–1510. <https://doi.org/10.1038/mt.2016.172>
  145. Kleinstiver BP, Pattanayak V, Prew MS, Tsai SQ, Nguyen NT, Zheng Z, et al. High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects. *Nature* 2016;**529**:490–495. <https://doi.org/10.1038/nature16526>
  146. Kawamata M, Suzuki HI, Kimura R, Suzuki A. Optimization of Cas9 activity through the addition of cytosine extensions to single-guide RNAs. *Nat Biomed Eng* 2023;**7**:672–691. <https://doi.org/10.1038/s41551-023-01011-7>
  147. Haapaniemi E, Botla S, Persson J, Schmierer B, Taipale J. CRISPR-Cas9 genome editing induces a p53-mediated DNA damage response. *Nat Med* 2018;**24**:927–930. <https://doi.org/10.1038/s41591-018-0049-z>
  148. Kosicki M, Tomberg K, Bradley A. Repair of double-strand breaks induced by CRISPR-Cas9 leads to large deletions and complex rearrangements. *Nat Biotechnol* 2018;**36**:765–771. <https://doi.org/10.1038/nbt.4192>
  149. Ihry RJ, Worringer KA, Salick MR, Frias E, Ho D, Theriault K, et al. p53 inhibits CRISPR-Cas9 engineering in human pluripotent stem cells. *Nat Med* 2018;**24**:939–946. <https://doi.org/10.1038/s41591-018-0050-6>
  150. Zuccaro MV, Xu J, Mitchell C, Marin D, Zimmerman R, Rana B, et al. Allele-specific chromosome removal after Cas9 cleavage in human embryos. *Cell* 2020;**183**:1650–1664.e15. <https://doi.org/10.1016/j.cell.2020.10.025>
  151. Guo C, Ma X, Gao F, Guo Y. Off-target effects in CRISPR/Cas9 gene editing. *Front Bioeng Biotechnol* 2023;**11**:1143157. <https://doi.org/10.3389/fbioe.2023.1143157>
  152. Hanlon KS, Kleinstiver BP, Garcia SP, Zaborowski MP, Volak A, Spirig SE, et al. High levels of AAV vector integration into CRISPR-induced DNA breaks. *Nat Commun* 2019;**10**:4439. <https://doi.org/10.1038/s41467-019-12449-2>
  153. Lu B, Javidi-Parsijani P, Makani V, Mehraein-Ghomi F, Sarhan WM, Sun D, et al. Delivering SaCas9 mRNA by lentivirus-like bionanoparticles for transient expression and efficient genome editing. *Nucleic Acids Res* 2019;**47**:e44. <https://doi.org/10.1093/nar/gkz093>
  154. Zuris JA, Thompson DB, Shu Y, Guilinger JP, Bessen JL, Hu JH, et al. Cationic lipid-mediated delivery of proteins enables efficient protein-based genome editing in vitro and in vivo. *Nat Biotechnol* 2015;**33**:73–80. <https://doi.org/10.1038/nbt.3081>
  155. American Society of Gene + Cell Therapy. Gene, Cell & RNA Therapy Landscape Report - Q2 2023 Quarterly Data Report. 2023.
  156. U.S. Food and Drug Administration. Cellular & Gene Therapy Guidances. <https://www.fda.gov/vaccines-blood-biologics/biologics-guidances/cellular-gene-therapy-guidances>
  157. Bender E. Regulating the gene-therapy revolution. *Nature* 2018;**564**:S20–S22. <https://doi.org/10.1038/d41586-018-07641-1>
  158. Kreutzer FP, Meinecke A, Schmidt K, Fiedler J, Thum T. Alternative strategies in cardiac preclinical research and new clinical trial formats. *Cardiovasc Res* 2022;**118**:746–762. <https://doi.org/10.1093/cvr/cvab075>
  159. Friedmann T. Changing roles for academia and industry in genetics and gene therapy. *Mol Ther* 2000;**1**:9–11. <https://doi.org/10.1006/mthe.1999.0015>
  160. Zacchigna S, Giacca M. Extra- and intracellular factors regulating cardiomyocyte proliferation in postnatal life. *Cardiovasc Res* 2014;**102**:312–320. <https://doi.org/10.1093/cvr/cvu057>
  161. Pupo A, Fernandez A, Low SH, Francois A, Suarez-Amaran L, Samulski RJ. AAV vectors: The Rubik's cube of human gene therapy. *Mol Ther* 2022;**30**:3515–3541. <https://doi.org/10.1016/j.ymthe.2022.09.015>
  162. Fang J, Islam W, Maeda H. Exploiting the dynamics of the EPR effect and strategies to improve the therapeutic effects of nanomedicines by using EPR effect enhancers. *Adv Drug Deliv Rev* 2020;**157**:142–160. <https://doi.org/10.1016/j.addr.2020.06.005>
  163. Hinkel R, Kupatt C. Selective pressure-regulated retroinfusion for gene therapy application in ischemic heart disease. *Methods Mol Biol* 2017;**1521**:249–260. [https://doi.org/10.1007/978-1-4939-6588-5\\_8uscore;18](https://doi.org/10.1007/978-1-4939-6588-5_8uscore;18)
  164. Vekstein AM, Wendell DC, DeLuca S, Yan R, Chen Y, Bishawi M, et al. Targeted delivery for cardiac regeneration: Comparison of intra-coronary infusion and intra-myocardial injection in porcine hearts. *Front Cardiovasc Med* 2022;**9**:833335. <https://doi.org/10.3389/fcvm.2022.833335>
  165. Aguero J, Ishikawa K, Hadri L, Santos-Gallego CG, Fish KM, Kohlbrenner E, et al. Intratracheal gene delivery of SERCA2a ameliorates chronic post-capillary pulmonary hypertension: a large animal model. *J Am Coll Cardiol* 2016;**67**:2032–2046. <https://doi.org/10.1016/j.jacc.2016.02.049>
  166. Schroder LC, Frank D, Muller OJ. Transcriptional targeting approaches in cardiac gene transfer using AAV vectors. *Pathogens* 2023;**12**:1301. <https://doi.org/10.3390/pathogens12111301>
  167. Singh D, Memari E, He S, Yusefi H, Helffeld B. Cardiac gene delivery using ultrasound: State of the field. *Mol Ther Methods Clin Dev* 2024;**32**:101277. <https://doi.org/10.1016/j.omtm.2024.101277>
  168. Abudayyeh OO, Gootenberg JS, Franklin B, Koob J, Kellner MJ, Ladha A, et al. A cytosine deaminase for programmable single-base RNA editing. *Science* 2019;**365**:382–386. <https://doi.org/10.1126/science.aax7063>
  169. Birgaoanu M, Sachse M, Gatsiou A. RNA editing therapeutics: Advances, challenges and perspectives on combating heart disease. *Cardiovasc Drugs Ther* 2023;**37**:401–411. <https://doi.org/10.1007/s10557-022-07391-3>
  170. Cox DBT, Gootenberg JS, Abudayyeh OO, Franklin B, Kellner MJ, Joung J, et al. RNA editing with CRISPR-Cas13. *Science* 2017;**358**:1019–1027. <https://doi.org/10.1126/science.aaq0180>
  171. Gatsiou A, Stellos K. RNA modifications in cardiovascular health and disease. *Nat Rev Cardiol* 2023;**20**:325–346. <https://doi.org/10.1038/s41569-022-00804-8>

172. Gatsiou A, Tual-Chalot S, Napoli M, Ortega-Gomez A, Regen T, Badolia R, et al. The RNA editor ADAR2 promotes immune cell trafficking by enhancing endothelial responses to interleukin-6 during sterile inflammation. *Immunity* 2023;**56**:e911. <https://doi.org/10.1016/j.immuni.2023.03.021>
173. Liu XM, Zhou J, Mao Y, Ji Q, Qian SB. Programmable RNA N<sup>6</sup>-methyladenosine editing by CRISPR-Cas9 conjugates. *Nat Chem Biol* 2019;**15**:865–871. <https://doi.org/10.1038/s41589-019-0327-1>
174. Rauch S, He E, Srienc M, Zhou H, Zhang Z, Dickinson BC. Programmable RNA-guided RNA effector proteins built from human parts. *Cell* 2019;**178**:122–134.e12. <https://doi.org/10.1016/j.cell.2019.05.049>
175. Merkle T, Merz S, Reautschnig P, Blaha A, Li Q, Vogel P, et al. Precise RNA editing by recruiting endogenous ADARs with antisense oligonucleotides. *Nat Biotechnol* 2019;**37**:133–138. <https://doi.org/10.1038/s41587-019-0013-6>
176. Qu L, Yi Z, Zhu S, Wang C, Cao Z, Zhou Z, et al. Programmable RNA editing by recruiting endogenous ADAR using engineered RNAs. *Nat Biotechnol* 2019;**37**:1059–1069. <https://doi.org/10.1038/s41587-019-0178-z>
177. Aquino-Jarquin G. Novel engineered programmable systems for ADAR-mediated RNA editing. *Mol Ther Nucleic Acids* 2020;**19**:1065–1072. <https://doi.org/10.1016/j.omtn.2019.12.042>
178. Watts GF, Schwabe C, Scott R, Gladding PA, Sullivan D, Baker J, et al. RNA interference targeting ANGPTL3 for triglyceride and cholesterol lowering: Phase 1 basket trial cohorts. *Nat Med* 2023;**29**:2216–2223. <https://doi.org/10.1038/s41591-023-02494-2>